<?xml version='1.0' encoding='UTF-8'?>
<document id="quantitative"><sentence id="quantitative.s0" text="Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%"><entity charOffset="20-31" id="quantitative.s0.e0" text="propoxyphene" type="active-ingredient" /><entity charOffset="79-88" id="quantitative.s0.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s0.e0" e2="quantitative.s0.e1" id="quantitative.s0.p0" /></sentence><sentence id="quantitative.s1" text="The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day."><entity charOffset="42-51" id="quantitative.s1.e0" text="imipramine" type="active-ingredient" /><entity charOffset="182-191" id="quantitative.s1.e1" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s1.e0" e2="quantitative.s1.e1" id="quantitative.s1.p0" /></sentence><sentence id="quantitative.s2" text="The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day"><entity charOffset="182-191" id="quantitative.s2.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="57-67" id="quantitative.s2.e1" text="desipramine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s2.e0" e2="quantitative.s2.e1" id="quantitative.s2.p0" /></sentence><sentence id="quantitative.s3" text="oadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%"><entity charOffset="76-85" id="quantitative.s3.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="19-28" id="quantitative.s3.e1" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s3.e0" e2="quantitative.s3.e1" id="quantitative.s3.p0" /></sentence><sentence id="quantitative.s4" text="Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%"><entity charOffset="90-99" id="quantitative.s4.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="20-30" id="quantitative.s4.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s4.e0" e2="quantitative.s4.e1" id="quantitative.s4.p0" /></sentence><sentence id="quantitative.s5" text="Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects"><entity charOffset="131-139" id="quantitative.s5.e0" text="sirolimus" type="active-ingredient" /><entity charOffset="35-46" id="quantitative.s5.e1" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s5.e0" e2="quantitative.s5.e1" id="quantitative.s5.p0" /></sentence><sentence id="quantitative.s6" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin"><entity charOffset="0-10" id="quantitative.s6.e0" text="Atomoxetine" type="active-ingredient" /><entity charOffset="52-71" id="quantitative.s6.e1" text="acetylsalicylic acid" type="active-ingredient" /><pair ddi="false" e1="quantitative.s6.e0" e2="quantitative.s6.e1" id="quantitative.s6.p0" /></sentence><sentence id="quantitative.s7" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin"><entity charOffset="0-10" id="quantitative.s7.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s7.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="52-71" id="quantitative.s7.e2" text="acetylsalicylic acid" type="active-ingredient" /><pair ddi="false" e1="quantitative.s7.e1" e2="quantitative.s7.e2" id="quantitative.s7.p0" /></sentence><sentence id="quantitative.s8" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin"><entity charOffset="74-82" id="quantitative.s8.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s8.e1" text="Atomoxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s8.e0" e2="quantitative.s8.e1" id="quantitative.s8.p0" /></sentence><sentence id="quantitative.s9" text="Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability"><entity charOffset="100-124" id="quantitative.s9.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="71-80" id="quantitative.s9.e1" text="omeprazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s9.e0" e2="quantitative.s9.e1" id="quantitative.s9.p0" /></sentence><sentence id="quantitative.s10" text="Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine"><entity charOffset="20-44" id="quantitative.s10.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="81-91" id="quantitative.s10.e1" text="desipramine" type="active-ingredient" /><entity charOffset="202-212" id="quantitative.s10.e2" text="desipramine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s10.e0" e2="quantitative.s10.e2" id="quantitative.s10.p0" /></sentence><sentence id="quantitative.s11" text="Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam"><entity charOffset="20-44" id="quantitative.s11.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="75-83" id="quantitative.s11.e1" text="midazolam" type="active-ingredient" /><entity charOffset="190-198" id="quantitative.s11.e2" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s11.e0" e2="quantitative.s11.e2" id="quantitative.s11.p0" /></sentence><sentence id="quantitative.s12" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin"><entity charOffset="88-95" id="quantitative.s12.e0" text="diazepam" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s12.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s12.e2" text="atomoxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s12.e0" e2="quantitative.s12.e2" id="quantitative.s12.p0" /></sentence><sentence id="quantitative.s13" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin"><entity charOffset="88-95" id="quantitative.s13.e0" text="diazepam" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s13.e1" text="Atomoxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s13.e0" e2="quantitative.s13.e1" id="quantitative.s13.p0" /></sentence><sentence id="quantitative.s14" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone"><entity charOffset="45-54" id="quantitative.s14.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="68-78" id="quantitative.s14.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="157-167" id="quantitative.s14.e2" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s14.e0" e2="quantitative.s14.e2" id="quantitative.s14.p0" /></sentence><sentence id="quantitative.s15" text="Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability"><entity charOffset="100-124" id="quantitative.s15.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="31-49" id="quantitative.s15.e1" text="magnesium hydroxide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s15.e0" e2="quantitative.s15.e1" id="quantitative.s15.p0" /></sentence><sentence id="quantitative.s16" text="Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability"><entity charOffset="100-124" id="quantitative.s16.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><pair ddi="false" e1="quantitative.s16.e0" e2="quantitative.s16.e0" id="quantitative.s16.p0" /></sentence><sentence id="quantitative.s17" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin"><entity charOffset="0-10" id="quantitative.s17.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s17.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="42-49" id="quantitative.s17.e2" text="warfarin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s17.e1" e2="quantitative.s17.e2" id="quantitative.s17.p0" /></sentence><sentence id="quantitative.s18" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin"><entity charOffset="74-82" id="quantitative.s18.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s18.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s18.e2" text="atomoxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s18.e0" e2="quantitative.s18.e2" id="quantitative.s18.p0" /></sentence><sentence id="quantitative.s19" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone"><entity charOffset="68-78" id="quantitative.s19.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="157-167" id="quantitative.s19.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="31-40" id="quantitative.s19.e2" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s19.e1" e2="quantitative.s19.e2" id="quantitative.s19.p0" /></sentence><sentence id="quantitative.s20" text="Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin"><entity charOffset="0-10" id="quantitative.s20.e0" text="Atomoxetine" type="active-ingredient" /><entity charOffset="42-49" id="quantitative.s20.e1" text="warfarin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s20.e0" e2="quantitative.s20.e1" id="quantitative.s20.p0" /></sentence><sentence id="quantitative.s21" text="study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction"><entity charOffset="27-45" id="quantitative.s21.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="119-127" id="quantitative.s21.e1" text="lorazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s21.e0" e2="quantitative.s21.e1" id="quantitative.s21.p0" /></sentence><sentence id="quantitative.s22" text="Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other"><entity charOffset="39-45" id="quantitative.s22.e0" text="ethanol" type="active-ingredient" /><entity charOffset="136-154" id="quantitative.s22.e1" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s22.e0" e2="quantitative.s22.e1" id="quantitative.s22.p0" /></sentence><sentence id="quantitative.s23" text="Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol"><entity charOffset="60-67" id="quantitative.s23.e0" text="atenolol" type="active-ingredient" /><entity charOffset="136-143" id="quantitative.s23.e1" text="atenolol" type="active-ingredient" /><entity charOffset="20-38" id="quantitative.s23.e2" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s23.e1" e2="quantitative.s23.e2" id="quantitative.s23.p0" /></sentence><sentence id="quantitative.s24" text="Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations"><entity charOffset="59-69" id="quantitative.s24.e0" text="propranolol" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s24.e1" text="propranolol" type="active-ingredient" /><entity charOffset="20-38" id="quantitative.s24.e2" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s24.e1" e2="quantitative.s24.e2" id="quantitative.s24.p0" /></sentence><sentence id="quantitative.s25" text="Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin"><entity charOffset="18-36" id="quantitative.s25.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="161-167" id="quantitative.s25.e1" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s25.e0" e2="quantitative.s25.e1" id="quantitative.s25.p0" /></sentence><sentence id="quantitative.s26" text="In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone"><entity charOffset="66-72" id="quantitative.s26.e0" text="tacrine" type="active-ingredient" /><entity charOffset="189-195" id="quantitative.s26.e1" text="tacrine" type="active-ingredient" /><entity charOffset="259-265" id="quantitative.s26.e2" text="tacrine" type="active-ingredient" /><entity charOffset="83-93" id="quantitative.s26.e3" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s26.e2" e2="quantitative.s26.e3" id="quantitative.s26.p0" /></sentence><sentence id="quantitative.s27" text=" study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. "><entity charOffset="28-46" id="quantitative.s27.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="120-128" id="quantitative.s27.e1" text="lorazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s27.e0" e2="quantitative.s27.e1" id="quantitative.s27.p0" /></sentence><sentence id="quantitative.s28" text="Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other"><entity charOffset="39-45" id="quantitative.s28.e0" text="ethanol" type="active-ingredient" /><entity charOffset="136-154" id="quantitative.s28.e1" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s28.e0" e2="quantitative.s28.e1" id="quantitative.s28.p0" /></sentence><sentence id="quantitative.s29" text="SEPTRA may inhibit the hepatic metabolism of phenytoin. SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%"><entity charOffset="0-5" id="quantitative.s29.e0" text="SEPTRA" type="drug-product" /><entity charOffset="56-61" id="quantitative.s29.e1" text="SEPTRA" type="drug-product" /><entity charOffset="45-53" id="quantitative.s29.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="113-121" id="quantitative.s29.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="158-166" id="quantitative.s29.e4" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s29.e1" e2="quantitative.s29.e4" id="quantitative.s29.p0" /></sentence><sentence id="quantitative.s30" text="Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold"><entity charOffset="33-44" id="quantitative.s30.e0" text="theophylline" type="active-ingredient" /><entity charOffset="56-67" id="quantitative.s30.e1" text="theophylline" type="active-ingredient" /><entity charOffset="110-121" id="quantitative.s30.e2" text="theophylline" type="active-ingredient" /><entity charOffset="20-26" id="quantitative.s30.e3" text="tacrine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s30.e2" e2="quantitative.s30.e3" id="quantitative.s30.p0" /></sentence><sentence id="quantitative.s31" text="Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol"><entity charOffset="135-144" id="quantitative.s31.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s31.e1" text="citalopram" type="active-ingredient" /><pair ddi="true" e1="quantitative.s31.e0" e2="quantitative.s31.e1" id="quantitative.s31.p0" /></sentence><sentence id="quantitative.s32" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram."><entity charOffset="27-36" id="quantitative.s32.e0" text="citalopram" type="active-ingredient" /><entity charOffset="202-211" id="quantitative.s32.e1" text="citalopram" type="active-ingredient" /><entity charOffset="50-61" id="quantitative.s32.e2" text="ketoconazole" type="active-ingredient" /><entity charOffset="102-113" id="quantitative.s32.e3" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s32.e1" e2="quantitative.s32.e3" id="quantitative.s32.p0" /></sentence><sentence id="quantitative.s33" text="Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram"><entity charOffset="27-36" id="quantitative.s33.e0" text="citalopram" type="active-ingredient" /><entity charOffset="202-211" id="quantitative.s33.e1" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s33.e1" e2="quantitative.s33.e1" id="quantitative.s33.p0" /></sentence><sentence id="quantitative.s34" text="Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate"><entity charOffset="90-97" id="quantitative.s34.e0" text="warfarin" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s34.e1" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s34.e0" e2="quantitative.s34.e1" id="quantitative.s34.p0" /></sentence><sentence id="quantitative.s35" text="Citalopram did not alter the mean AUC or Cmax of pimozide"><entity charOffset="0-9" id="quantitative.s35.e0" text="Citalopram" type="active-ingredient" /><entity charOffset="49-56" id="quantitative.s35.e1" text="pimozide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s35.e0" e2="quantitative.s35.e1" id="quantitative.s35.p0" /></sentence><sentence id="quantitative.s36" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin"><entity charOffset="104-110" id="quantitative.s36.e0" text="digoxin" type="active-ingredient" /><entity charOffset="208-214" id="quantitative.s36.e1" text="digoxin" type="active-ingredient" /><entity charOffset="50-59" id="quantitative.s36.e2" text="citalopram" type="active-ingredient" /><entity charOffset="89-98" id="quantitative.s36.e3" text="citalopram" type="active-ingredient" /><entity charOffset="194-203" id="quantitative.s36.e4" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s36.e1" e2="quantitative.s36.e4" id="quantitative.s36.p0" /></sentence><sentence id="quantitative.s37" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin"><entity charOffset="104-110" id="quantitative.s37.e0" text="digoxin" type="active-ingredient" /><entity charOffset="208-214" id="quantitative.s37.e1" text="digoxin" type="active-ingredient" /><entity charOffset="50-59" id="quantitative.s37.e2" text="citalopram" type="active-ingredient" /><entity charOffset="89-98" id="quantitative.s37.e3" text="citalopram" type="active-ingredient" /><entity charOffset="194-203" id="quantitative.s37.e4" text="citalopram" type="active-ingredient" /><pair ddi="false" e1="quantitative.s37.e1" e2="quantitative.s37.e4" id="quantitative.s37.p0" /></sentence><sentence id="quantitative.s38" text="In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively"><entity charOffset="50-59" id="quantitative.s38.e0" text="citalopram" type="active-ingredient" /><entity charOffset="149-158" id="quantitative.s38.e1" text="citalopram" type="active-ingredient" /><entity charOffset="100-109" id="quantitative.s38.e2" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s38.e1" e2="quantitative.s38.e2" id="quantitative.s38.p0" /></sentence><sentence id="quantitative.s39" text="For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone"><entity charOffset="4-17" id="quantitative.s39.e0" text="clarithromycin" type="active-ingredient" /><entity charOffset="123-136" id="quantitative.s39.e1" text="clarithromycin" type="active-ingredient" /><entity charOffset="181-194" id="quantitative.s39.e2" text="clarithromycin" type="active-ingredient" /><entity charOffset="160-169" id="quantitative.s39.e3" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s39.e2" e2="quantitative.s39.e3" id="quantitative.s39.p0" /></sentence><sentence id="quantitative.s40" text="For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater."><entity charOffset="160-169" id="quantitative.s40.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="250-274" id="quantitative.s40.e1" text="14-hydroxy-clarithromycin" type="metabolite" /><pair ddi="true" e1="quantitative.s40.e0" e2="quantitative.s40.e1" id="quantitative.s40.p0" /></sentence><sentence id="quantitative.s41" text="Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%."><entity charOffset="56-65" id="quantitative.s41.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s41.e1" text="atazanavir" type="active-ingredient" /><entity charOffset="91-100" id="quantitative.s41.e2" text="atazanavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s41.e0" e2="quantitative.s41.e2" id="quantitative.s41.p0" /></sentence><sentence id="quantitative.s42" text="Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8"><entity charOffset="58-67" id="quantitative.s42.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s42.e1" text="nelfinavir" type="active-ingredient" /><entity charOffset="177-186" id="quantitative.s42.e2" text="nelfinavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s42.e0" e2="quantitative.s42.e2" id="quantitative.s42.p0" /></sentence><sentence id="quantitative.s43" text="Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8"><entity charOffset="192-193" id="quantitative.s43.e0" text="M8" type="metabolite" /><entity charOffset="58-67" id="quantitative.s43.e1" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s43.e0" e2="quantitative.s43.e1" id="quantitative.s43.p0" /></sentence><sentence id="quantitative.s44" text="When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole"><entity charOffset="5-16" id="quantitative.s44.e0" text="voriconazole" type="active-ingredient" /><entity charOffset="347-358" id="quantitative.s44.e1" text="voriconazole" type="active-ingredient" /><entity charOffset="77-86" id="quantitative.s44.e2" text="omeprazole" type="active-ingredient" /><entity charOffset="201-210" id="quantitative.s44.e3" text="omeprazole" type="active-ingredient" /><entity charOffset="318-327" id="quantitative.s44.e4" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s44.e1" e2="quantitative.s44.e4" id="quantitative.s44.p0" /></sentence><sentence id="quantitative.s45" text="Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure"><entity charOffset="30-39" id="quantitative.s45.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="141-150" id="quantitative.s45.e1" text="omeprazole" type="active-ingredient" /><entity charOffset="45-56" id="quantitative.s45.e2" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s45.e1" e2="quantitative.s45.e2" id="quantitative.s45.p0" /></sentence><sentence id="quantitative.s46" text="For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15"><entity charOffset="245-254" id="quantitative.s46.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="40-49" id="quantitative.s46.e1" text="saquinavir" type="active-ingredient" /><entity charOffset="189-198" id="quantitative.s46.e2" text="saquinavir" type="active-ingredient" /><pair ddi="true" e1="quantitative.s46.e0" e2="quantitative.s46.e2" id="quantitative.s46.p0" /></sentence><sentence id="quantitative.s47" text="A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively"><entity charOffset="111-119" id="quantitative.s47.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="55-62" id="quantitative.s47.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s47.e0" e2="quantitative.s47.e1" id="quantitative.s47.p0" /></sentence><sentence id="quantitative.s48" text="A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively"><entity charOffset="99-107" id="quantitative.s48.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="55-66" id="quantitative.s48.e1" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s48.e0" e2="quantitative.s48.e1" id="quantitative.s48.p0" /></sentence><sentence id="quantitative.s49" text="Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol"><entity charOffset="22-28" id="quantitative.s49.e0" text="antacid" type="drug-product" /><entity charOffset="46-52" id="quantitative.s49.e1" text="sotalol" type="active-ingredient" /><entity charOffset="115-121" id="quantitative.s49.e2" text="sotalol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s49.e0" e2="quantitative.s49.e2" id="quantitative.s49.p0" /></sentence><sentence id="quantitative.s50" text="Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest."><entity charOffset="18-24" id="quantitative.s50.e0" text="sotalol" type="active-ingredient" /><entity charOffset="44-101" id="quantitative.s50.e1" text="antacids containing aluminum oxide and magnesium hydroxide" type="drug-product" /><pair ddi="true" e1="quantitative.s50.e0" e2="quantitative.s50.e1" id="quantitative.s50.p0" /></sentence><sentence id="quantitative.s51" text="Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13)."><entity charOffset="23-33" id="quantitative.s51.e0" text="risperidone" type="active-ingredient" /><entity charOffset="128-134" id="quantitative.s51.e1" text="lithium" type="active-ingredient" /><pair ddi="false" e1="quantitative.s51.e0" e2="quantitative.s51.e1" id="quantitative.s51.p0" /></sentence><sentence id="quantitative.s52" text="Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively."><entity charOffset="120-130" id="quantitative.s52.e0" text="risperidone" type="active-ingredient" /><entity charOffset="34-43" id="quantitative.s52.e1" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s52.e0" e2="quantitative.s52.e1" id="quantitative.s52.p0" /></sentence><sentence id="quantitative.s53" text="However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined"><entity charOffset="62-81" id="quantitative.s53.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="9-18" id="quantitative.s53.e1" text="cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s53.e0" e2="quantitative.s53.e1" id="quantitative.s53.p0" /></sentence><sentence id="quantitative.s54" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%"><entity charOffset="84-94" id="quantitative.s54.e0" text="risperidone" type="active-ingredient" /><entity charOffset="109-119" id="quantitative.s54.e1" text="risperidone" type="active-ingredient" /><entity charOffset="0-12" id="quantitative.s54.e2" text="Carbamazepine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s54.e1" e2="quantitative.s54.e2" id="quantitative.s54.p0" /></sentence><sentence id="quantitative.s55" text="n drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, "><entity charOffset="28-38" id="quantitative.s55.e0" text="risperidone" type="active-ingredient" /><entity charOffset="93-101" id="quantitative.s55.e1" text="donepezil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s55.e0" e2="quantitative.s55.e1" id="quantitative.s55.p0" /></sentence><sentence id="quantitative.s56" text="Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone"><entity charOffset="54-73" id="quantitative.s56.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="0-9" id="quantitative.s56.e1" text="Fluoxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s56.e0" e2="quantitative.s56.e1" id="quantitative.s56.p0" /></sentence><sentence id="quantitative.s57" text="However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone"><entity charOffset="116-126" id="quantitative.s57.e0" text="risperidone" type="active-ingredient" /><entity charOffset="37-45" id="quantitative.s57.e1" text="valproate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s57.e0" e2="quantitative.s57.e1" id="quantitative.s57.p0" /></sentence><sentence id="quantitative.s58" text="Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively."><entity charOffset="0-9" id="quantitative.s58.e0" text="Cimetidine" type="active-ingredient" /><entity charOffset="59-69" id="quantitative.s58.e1" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s58.e0" e2="quantitative.s58.e1" id="quantitative.s58.p0" /></sentence><sentence id="quantitative.s59" text="Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined"><entity charOffset="0-12" id="quantitative.s59.e0" text="Amitriptyline" type="active-ingredient" /><entity charOffset="84-103" id="quantitative.s59.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="false" e1="quantitative.s59.e0" e2="quantitative.s59.e1" id="quantitative.s59.p0" /></sentence><sentence id="quantitative.s60" text="Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively."><entity charOffset="59-69" id="quantitative.s60.e0" text="risperidone" type="active-ingredient" /><entity charOffset="15-24" id="quantitative.s60.e1" text="ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s60.e0" e2="quantitative.s60.e1" id="quantitative.s60.p0" /></sentence><sentence id="quantitative.s61" text="n drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine,"><entity charOffset="28-38" id="quantitative.s61.e0" text="risperidone" type="active-ingredient" /><entity charOffset="107-117" id="quantitative.s61.e1" text="galantamine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s61.e0" e2="quantitative.s61.e1" id="quantitative.s61.p0" /></sentence><sentence id="quantitative.s62" text="Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%"><entity charOffset="100-119" id="quantitative.s62.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="0-12" id="quantitative.s62.e1" text="Carbamazepine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s62.e0" e2="quantitative.s62.e1" id="quantitative.s62.p0" /></sentence><sentence id="quantitative.s63" text="Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21)"><entity charOffset="23-33" id="quantitative.s63.e0" text="risperidone" type="active-ingredient" /><entity charOffset="136-144" id="quantitative.s63.e1" text="valproate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s63.e0" e2="quantitative.s63.e1" id="quantitative.s63.p0" /></sentence><sentence id="quantitative.s64" text="Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%"><entity charOffset="0-9" id="quantitative.s64.e0" text="Paroxetine" type="active-ingredient" /><entity charOffset="40-59" id="quantitative.s64.e1" text="9-hydroxyrisperidone" type="metabolite" /><pair ddi="true" e1="quantitative.s64.e0" e2="quantitative.s64.e1" id="quantitative.s64.p0" /></sentence><sentence id="quantitative.s65" text="Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin"><entity charOffset="103-109" id="quantitative.s65.e0" text="digoxin" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s65.e1" text="Risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s65.e0" e2="quantitative.s65.e1" id="quantitative.s65.p0" /></sentence><sentence id="quantitative.s66" text="Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined"><entity charOffset="0-12" id="quantitative.s66.e0" text="Amitriptyline" type="active-ingredient" /><entity charOffset="53-63" id="quantitative.s66.e1" text="risperidone" type="active-ingredient" /><entity charOffset="68-78" id="quantitative.s66.e2" text="risperidone" type="active-ingredient" /><entity charOffset="93-103" id="quantitative.s66.e3" text="risperidone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s66.e0" e2="quantitative.s66.e3" id="quantitative.s66.p0" /></sentence><sentence id="quantitative.s67" text="whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%"><entity charOffset="56-75" id="quantitative.s67.e0" text="9-hydroxyrisperidone" type="metabolite" /><entity charOffset="8-17" id="quantitative.s67.e1" text="ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s67.e0" e2="quantitative.s67.e1" id="quantitative.s67.p0" /></sentence><sentence id="quantitative.s68" text="Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively."><entity charOffset="120-130" id="quantitative.s68.e0" text="risperidone" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s68.e1" text="Fluoxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s68.e0" e2="quantitative.s68.e1" id="quantitative.s68.p0" /></sentence><sentence id="quantitative.s69" text="Nefazodone plasma concentrations were unaffected by alprazolam"><entity charOffset="0-9" id="quantitative.s69.e0" text="Nefazodone" type="active-ingredient" /><entity charOffset="52-61" id="quantitative.s69.e1" text="alprazolam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s69.e0" e2="quantitative.s69.e1" id="quantitative.s69.p0" /></sentence><sentence id="quantitative.s70" text="When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold"><entity charOffset="31-40" id="quantitative.s70.e0" text="nefazodone" type="active-ingredient" /><entity charOffset="5-14" id="quantitative.s70.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="139-148" id="quantitative.s70.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s70.e0" e2="quantitative.s70.e2" id="quantitative.s70.p0" /></sentence><sentence id="quantitative.s71" text="Nefazodone plasma concentrations were unaffected by triazolam"><entity charOffset="0-9" id="quantitative.s71.e0" text="Nefazodone" type="active-ingredient" /><entity charOffset="52-60" id="quantitative.s71.e1" text="triazolam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s71.e0" e2="quantitative.s71.e1" id="quantitative.s71.p0" /></sentence><sentence id="quantitative.s72" text="Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%)"><entity charOffset="66-76" id="quantitative.s72.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s72.e1" text="Ranitidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s72.e0" e2="quantitative.s72.e1" id="quantitative.s72.p0" /></sentence><sentence id="quantitative.s73" text="Immediate release nisoldipine increased plasma quinidine concentrations by about 20%"><entity charOffset="0-28" id="quantitative.s73.e0" text="Immediate release nisoldipine" type="drug-product" /><entity charOffset="47-55" id="quantitative.s73.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s73.e0" e2="quantitative.s73.e1" id="quantitative.s73.p0" /></sentence><sentence id="quantitative.s74" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%"><entity charOffset="63-73" id="quantitative.s74.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s74.e1" text="Quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s74.e0" e2="quantitative.s74.e1" id="quantitative.s74.p0" /></sentence><sentence id="quantitative.s75" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration"><entity charOffset="63-73" id="quantitative.s75.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s75.e1" text="Quinidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s75.e0" e2="quantitative.s75.e1" id="quantitative.s75.p0" /></sentence><sentence id="quantitative.s76" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily"><entity charOffset="40-50" id="quantitative.s76.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="100-109" id="quantitative.s76.e1" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s76.e0" e2="quantitative.s76.e1" id="quantitative.s76.p0" /></sentence><sentence id="quantitative.s77" text="Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state."><entity charOffset="39-48" id="quantitative.s77.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="126-137" id="quantitative.s77.e1" text="procyclidine" type="active-ingredient" /><entity charOffset="210-221" id="quantitative.s77.e2" text="procyclidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s77.e0" e2="quantitative.s77.e2" id="quantitative.s77.p0" /></sentence><sentence id="quantitative.s78" text="In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged"><entity charOffset="17-27" id="quantitative.s78.e0" text="haloperidol" type="active-ingredient" /><entity charOffset="94-104" id="quantitative.s78.e1" text="haloperidol" type="active-ingredient" /><entity charOffset="73-83" id="quantitative.s78.e2" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s78.e1" e2="quantitative.s78.e2" id="quantitative.s78.p0" /></sentence><sentence id="quantitative.s79" text="A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively"><entity charOffset="272-274" id="quantitative.s79.e0" text="ODV" type="metabolite" /><entity charOffset="425-427" id="quantitative.s79.e1" text="ODV" type="metabolite" /><entity charOffset="29-40" id="quantitative.s79.e2" text="ketoconazole" type="active-ingredient" /><entity charOffset="322-333" id="quantitative.s79.e3" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s79.e1" e2="quantitative.s79.e3" id="quantitative.s79.p0" /></sentence><sentence id="quantitative.s80" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects"><entity charOffset="97-104" id="quantitative.s80.e0" text="diazepam" type="active-ingredient" /><entity charOffset="177-179" id="quantitative.s80.e1" text="ODV" type="metabolite" /><pair ddi="false" e1="quantitative.s80.e0" e2="quantitative.s80.e1" id="quantitative.s80.p0" /></sentence><sentence id="quantitative.s81" text="Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam"><entity charOffset="68-75" id="quantitative.s81.e0" text="diazepam" type="active-ingredient" /><entity charOffset="112-119" id="quantitative.s81.e1" text="diazepam" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s81.e2" text="Venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s81.e1" e2="quantitative.s81.e2" id="quantitative.s81.p0" /></sentence><sentence id="quantitative.s82" text="Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19"><entity charOffset="46-53" id="quantitative.s82.e0" text="diazepam" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s82.e1" text="Venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s82.e0" e2="quantitative.s82.e1" id="quantitative.s82.p0" /></sentence><sentence id="quantitative.s83" text="However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine"><entity charOffset="9-19" id="quantitative.s83.e0" text="desipramine" type="active-ingredient" /><entity charOffset="83-93" id="quantitative.s83.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s83.e0" e2="quantitative.s83.e1" id="quantitative.s83.p0" /></sentence><sentence id="quantitative.s84" text="The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects."><entity charOffset="128-134" id="quantitative.s84.e0" text="lithium" type="active-ingredient" /><entity charOffset="37-47" id="quantitative.s84.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s84.e0" e2="quantitative.s84.e1" id="quantitative.s84.p0" /></sentence><sentence id="quantitative.s85" text="Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%"><entity charOffset="30-39" id="quantitative.s85.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="45-55" id="quantitative.s85.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="147-157" id="quantitative.s85.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="205-215" id="quantitative.s85.e3" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s85.e0" e2="quantitative.s85.e3" id="quantitative.s85.p0" /></sentence><sentence id="quantitative.s86" text="Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. "><entity charOffset="0-10" id="quantitative.s86.e0" text="Venlafaxine" type="active-ingredient" /><entity charOffset="122-132" id="quantitative.s86.e1" text="risperidone" type="active-ingredient" /><entity charOffset="211-221" id="quantitative.s86.e2" text="risperidone" type="active-ingredient" /><entity charOffset="268-278" id="quantitative.s86.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s86.e0" e2="quantitative.s86.e3" id="quantitative.s86.p0" /></sentence><sentence id="quantitative.s87" text="A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects"><entity charOffset="17-23" id="quantitative.s87.e0" text="ethanol" type="active-ingredient" /><entity charOffset="92-113" id="quantitative.s87.e1" text="O-desmethylvenlafaxine" type="metabolite" /><pair ddi="false" e1="quantitative.s87.e0" e2="quantitative.s87.e1" id="quantitative.s87.p0" /></sentence><sentence id="quantitative.s88" text="A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects"><entity charOffset="77-87" id="quantitative.s88.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="103-113" id="quantitative.s88.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="126-136" id="quantitative.s88.e2" text="venlafaxine" type="active-ingredient" /><entity charOffset="17-23" id="quantitative.s88.e3" text="ethanol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s88.e2" e2="quantitative.s88.e3" id="quantitative.s88.p0" /></sentence><sentence id="quantitative.s89" text="Imipramine did not affect the pharmacokinetics of venlafaxine and ODV"><entity charOffset="0-9" id="quantitative.s89.e0" text="Imipramine" type="active-ingredient" /><entity charOffset="66-68" id="quantitative.s89.e1" text="ODV" type="metabolite" /><pair ddi="false" e1="quantitative.s89.e0" e2="quantitative.s89.e1" id="quantitative.s89.p0" /></sentence><sentence id="quantitative.s90" text="Venlafaxine had no effect on the pharmacokinetics of lithium "><entity charOffset="53-59" id="quantitative.s90.e0" text="lithium" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s90.e1" text="Venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s90.e0" e2="quantitative.s90.e1" id="quantitative.s90.p0" /></sentence><sentence id="quantitative.s91" text="This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine"><entity charOffset="81-91" id="quantitative.s91.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="176-183" id="quantitative.s91.e1" text="diazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s91.e0" e2="quantitative.s91.e1" id="quantitative.s91.p0" /></sentence><sentence id="quantitative.s92" text="The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected"><entity charOffset="182-184" id="quantitative.s92.e0" text="ODV" type="metabolite" /><entity charOffset="128-134" id="quantitative.s92.e1" text="lithium" type="active-ingredient" /><pair ddi="false" e1="quantitative.s92.e0" e2="quantitative.s92.e1" id="quantitative.s92.p0" /></sentence><sentence id="quantitative.s93" text="Indinavir did not affect the pharmacokinetics of venlafaxine and ODV."><entity charOffset="65-67" id="quantitative.s93.e0" text="ODV" type="metabolite" /><entity charOffset="0-8" id="quantitative.s93.e1" text="Indinavir" type="active-ingredient" /><pair ddi="false" e1="quantitative.s93.e0" e2="quantitative.s93.e1" id="quantitative.s93.p0" /></sentence><sentence id="quantitative.s94" text="Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine"><entity charOffset="51-60" id="quantitative.s94.e0" text="imipramine" type="active-ingredient" /><entity charOffset="71-80" id="quantitative.s94.e1" text="imipramine" type="active-ingredient" /><entity charOffset="0-10" id="quantitative.s94.e2" text="Venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s94.e1" e2="quantitative.s94.e2" id="quantitative.s94.p0" /></sentence><sentence id="quantitative.s95" text=" In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide"><entity charOffset="162-182" id="quantitative.s95.e0" text="4-hydroxy-tolbutamide" type="metabolite" /><entity charOffset="10-20" id="quantitative.s95.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s95.e0" e2="quantitative.s95.e1" id="quantitative.s95.p0" /></sentence><sentence id="quantitative.s96" text="Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine"><entity charOffset="56-66" id="quantitative.s96.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="105-115" id="quantitative.s96.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s96.e2" text="Metoprolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s96.e1" e2="quantitative.s96.e2" id="quantitative.s96.p0" /></sentence><sentence id="quantitative.s97" text="This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine"><entity charOffset="81-91" id="quantitative.s97.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="190-200" id="quantitative.s97.e1" text="terfenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s97.e0" e2="quantitative.s97.e1" id="quantitative.s97.p0" /></sentence><sentence id="quantitative.s98" text="The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h"><entity charOffset="4-19" id="quantitative.s98.e0" text="2-OH-desipramine" type="metabolite" /><entity charOffset="64-74" id="quantitative.s98.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="112-122" id="quantitative.s98.e2" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s98.e0" e2="quantitative.s98.e2" id="quantitative.s98.p0" /></sentence><sentence id="quantitative.s99" text="In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax"><entity charOffset="175-183" id="quantitative.s99.e0" text="indinavir" type="active-ingredient" /><entity charOffset="207-215" id="quantitative.s99.e1" text="indinavir" type="active-ingredient" /><entity charOffset="36-46" id="quantitative.s99.e2" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s99.e1" e2="quantitative.s99.e2" id="quantitative.s99.p0" /></sentence><sentence id="quantitative.s100" text="Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol"><entity charOffset="79-88" id="quantitative.s100.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="259-268" id="quantitative.s100.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="376-385" id="quantitative.s100.e2" text="metoprolol" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s100.e3" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s100.e2" e2="quantitative.s100.e3" id="quantitative.s100.p0" /></sentence><sentence id="quantitative.s101" text="However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine."><entity charOffset="90-92" id="quantitative.s101.e0" text="ODV" type="metabolite" /><entity charOffset="29-38" id="quantitative.s101.e1" text="cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s101.e0" e2="quantitative.s101.e1" id="quantitative.s101.p0" /></sentence><sentence id="quantitative.s102" text="Indinavir did not affect the pharmacokinetics of venlafaxine and ODV"><entity charOffset="49-59" id="quantitative.s102.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s102.e1" text="Indinavir" type="active-ingredient" /><pair ddi="false" e1="quantitative.s102.e0" e2="quantitative.s102.e1" id="quantitative.s102.p0" /></sentence><sentence id="quantitative.s103" text=" In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide"><entity charOffset="10-20" id="quantitative.s103.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="114-124" id="quantitative.s103.e1" text="tolbutamide" type="active-ingredient" /><entity charOffset="172-182" id="quantitative.s103.e2" text="tolbutamide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s103.e0" e2="quantitative.s103.e2" id="quantitative.s103.p0" /></sentence><sentence id="quantitative.s104" text="Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine"><entity charOffset="0-9" id="quantitative.s104.e0" text="Metoprolol" type="active-ingredient" /><entity charOffset="94-115" id="quantitative.s104.e1" text="O-desmethylvenlafaxine" type="metabolite" /><pair ddi="false" e1="quantitative.s104.e0" e2="quantitative.s104.e1" id="quantitative.s104.p0" /></sentence><sentence id="quantitative.s105" text="Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam"><entity charOffset="103-119" id="quantitative.s105.e0" text="desmethyldiazepam" type="metabolite" /><entity charOffset="0-10" id="quantitative.s105.e1" text="Venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s105.e0" e2="quantitative.s105.e1" id="quantitative.s105.p0" /></sentence><sentence id="quantitative.s106" text="Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC"><entity charOffset="0-10" id="quantitative.s106.e0" text="Venlafaxine" type="active-ingredient" /><entity charOffset="160-170" id="quantitative.s106.e1" text="haloperidol" type="active-ingredient" /><entity charOffset="216-226" id="quantitative.s106.e2" text="haloperidol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s106.e0" e2="quantitative.s106.e2" id="quantitative.s106.p0" /></sentence><sentence id="quantitative.s107" text="A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively"><entity charOffset="78-88" id="quantitative.s107.e0" text="Venlafaxine" type="active-ingredient" /><entity charOffset="232-242" id="quantitative.s107.e1" text="Venlafaxine" type="active-ingredient" /><entity charOffset="259-269" id="quantitative.s107.e2" text="Venlafaxine" type="active-ingredient" /><entity charOffset="336-346" id="quantitative.s107.e3" text="Venlafaxine" type="active-ingredient" /><entity charOffset="29-40" id="quantitative.s107.e4" text="ketoconazole" type="active-ingredient" /><entity charOffset="322-333" id="quantitative.s107.e5" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s107.e3" e2="quantitative.s107.e5" id="quantitative.s107.p0" /></sentence><sentence id="quantitative.s108" text="However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone)"><entity charOffset="9-19" id="quantitative.s108.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="122-158" id="quantitative.s108.e1" text="risperidone plus 9-hydroxyrisperidone" type="metabolite" /><pair ddi="false" e1="quantitative.s108.e0" e2="quantitative.s108.e1" id="quantitative.s108.p0" /></sentence><sentence id="quantitative.s109" text="Imipramine did not affect the pharmacokinetics of venlafaxine and ODV."><entity charOffset="0-9" id="quantitative.s109.e0" text="Imipramine" type="active-ingredient" /><entity charOffset="50-60" id="quantitative.s109.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s109.e0" e2="quantitative.s109.e1" id="quantitative.s109.p0" /></sentence><sentence id="quantitative.s110" text="This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine"><entity charOffset="164-173" id="quantitative.s110.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="81-91" id="quantitative.s110.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s110.e0" e2="quantitative.s110.e1" id="quantitative.s110.p0" /></sentence><sentence id="quantitative.s111" text="This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate."><entity charOffset="127-134" id="quantitative.s111.e0" text="caffeine" type="active-ingredient" /><entity charOffset="81-91" id="quantitative.s111.e1" text="venlafaxine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s111.e0" e2="quantitative.s111.e1" id="quantitative.s111.p0" /></sentence><sentence id="quantitative.s112" text="Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects"><entity charOffset="34-44" id="quantitative.s112.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="162-172" id="quantitative.s112.e1" text="venlafaxine" type="active-ingredient" /><entity charOffset="97-104" id="quantitative.s112.e2" text="diazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s112.e1" e2="quantitative.s112.e2" id="quantitative.s112.p0" /></sentence><sentence id="quantitative.s113" text="In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged"><entity charOffset="73-83" id="quantitative.s113.e0" text="venlafaxine" type="active-ingredient" /><entity charOffset="17-27" id="quantitative.s113.e1" text="haloperidol" type="active-ingredient" /><entity charOffset="94-104" id="quantitative.s113.e2" text="haloperidol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s113.e0" e2="quantitative.s113.e2" id="quantitative.s113.p0" /></sentence><sentence id="quantitative.s114" text="Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine"><entity charOffset="0-10" id="quantitative.s114.e0" text="Venlafaxine" type="active-ingredient" /><entity charOffset="66-80" id="quantitative.s114.e1" text="2-OH-imipramine" type="metabolite" /><pair ddi="false" e1="quantitative.s114.e0" e2="quantitative.s114.e1" id="quantitative.s114.p0" /></sentence><sentence id="quantitative.s115" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate"><entity charOffset="148-164" id="quantitative.s115.e0" text="lithium carbonate" type="active-ingredient" /><entity charOffset="45-54" id="quantitative.s115.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="133-142" id="quantitative.s115.e2" text="paroxetine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s115.e0" e2="quantitative.s115.e2" id="quantitative.s115.p0" /></sentence><sentence id="quantitative.s116" text="A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate"><entity charOffset="148-164" id="quantitative.s116.e0" text="lithium carbonate" type="active-ingredient" /><entity charOffset="27-68" id="quantitative.s116.e1" text="immediate-release paroxetine hydrochloride" type="drug-product" /><pair ddi="false" e1="quantitative.s116.e0" e2="quantitative.s116.e1" id="quantitative.s116.p0" /></sentence><sentence id="quantitative.s117" text="An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics"><entity charOffset="93-102" id="quantitative.s117.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="167-176" id="quantitative.s117.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="108-118" id="quantitative.s117.e2" text="terfenadine" type="active-ingredient" /><entity charOffset="181-191" id="quantitative.s117.e3" text="terfenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s117.e1" e2="quantitative.s117.e3" id="quantitative.s117.p0" /></sentence><sentence id="quantitative.s118" text="In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold"><entity charOffset="183-202" id="quantitative.s118.e0" text="9-hydroxyrisperidone" type="active-ingredient" /><entity charOffset="317-336" id="quantitative.s118.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><entity charOffset="28-37" id="quantitative.s118.e2" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s118.e1" e2="quantitative.s118.e2" id="quantitative.s118.p0" /></sentence><sentence id="quantitative.s119" text="In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively"><entity charOffset="28-55" id="quantitative.s119.e0" text="immediate-release paroxetine" type="drug-product" /><entity charOffset="128-138" id="quantitative.s119.e1" text="desipramine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s119.e0" e2="quantitative.s119.e1" id="quantitative.s119.p0" /></sentence><sentence id="quantitative.s120" text="In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone"><entity charOffset="65-74" id="quantitative.s120.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="124-134" id="quantitative.s120.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="195-205" id="quantitative.s120.e2" text="atomoxetine" type="active-ingredient" /><entity charOffset="256-266" id="quantitative.s120.e3" text="atomoxetine" type="active-ingredient" /><entity charOffset="321-331" id="quantitative.s120.e4" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s120.e0" e2="quantitative.s120.e4" id="quantitative.s120.p0" /></sentence><sentence id="quantitative.s121" text="In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold"><entity charOffset="28-37" id="quantitative.s121.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="71-81" id="quantitative.s121.e1" text="risperidone" type="active-ingredient" /><entity charOffset="139-149" id="quantitative.s121.e2" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="quantitative.s121.e3" text="risperidone" type="active-ingredient" /><entity charOffset="300-310" id="quantitative.s121.e4" text="risperidone" type="active-ingredient" /><entity charOffset="326-336" id="quantitative.s121.e5" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s121.e0" e2="quantitative.s121.e5" id="quantitative.s121.p0" /></sentence><sentence id="quantitative.s122" text="When a single oral 30-mg dose of immediate-release paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone"><entity charOffset="82-90" id="quantitative.s122.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="33-60" id="quantitative.s122.e1" text="immediate-release paroxetine" type="drug-product" /><entity charOffset="231-258" id="quantitative.s122.e2" text="immediate-release paroxetine" type="drug-product" /><pair ddi="true" e1="quantitative.s122.e0" e2="quantitative.s122.e2" id="quantitative.s122.p0" /></sentence><sentence id="quantitative.s123" text="In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone."><entity charOffset="55-63" id="quantitative.s123.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="141-149" id="quantitative.s123.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s123.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="85-94" id="quantitative.s123.e3" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s123.e2" e2="quantitative.s123.e3" id="quantitative.s123.p0" /></sentence><sentence id="quantitative.s124" text="When a single oral 30-mg dose of immediate-release paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone"><entity charOffset="33-60" id="quantitative.s124.e0" text="immediate-release paroxetine" type="drug-product" /><entity charOffset="82-94" id="quantitative.s124.e1" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="quantitative.s124.e0" e2="quantitative.s124.e1" id="quantitative.s124.p0" /></sentence><sentence id="quantitative.s125" text="In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone"><entity charOffset="166-173" id="quantitative.s125.e0" text="pimozide" type="active-ingredient" /><entity charOffset="213-220" id="quantitative.s125.e1" text="pimozide" type="active-ingredient" /><entity charOffset="263-270" id="quantitative.s125.e2" text="pimozide" type="active-ingredient" /><entity charOffset="51-92" id="quantitative.s125.e3" text="immediate-release paroxetine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s125.e2" e2="quantitative.s125.e3" id="quantitative.s125.p0" /></sentence><sentence id="quantitative.s126" text="The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81)"><entity charOffset="36-44" id="quantitative.s126.e0" text="glipizide" type="active-ingredient" /><entity charOffset="56-66" id="quantitative.s126.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s126.e0" e2="quantitative.s126.e1" id="quantitative.s126.p0" /></sentence><sentence id="quantitative.s127" text="Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine"><entity charOffset="63-74" id="quantitative.s127.e0" text="mesoridazine" type="metabolite" /><entity charOffset="142-152" id="quantitative.s127.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s127.e0" e2="quantitative.s127.e1" id="quantitative.s127.p0" /></sentence><sentence id="quantitative.s128" text="Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine"><entity charOffset="80-92" id="quantitative.s128.e0" text="sulforidazine" type="metabolite" /><entity charOffset="142-152" id="quantitative.s128.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s128.e0" e2="quantitative.s128.e1" id="quantitative.s128.p0" /></sentence><sentence id="quantitative.s129" text="Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine"><entity charOffset="18-29" id="quantitative.s129.e0" text="thioridazine" type="active-ingredient" /><entity charOffset="142-152" id="quantitative.s129.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s129.e0" e2="quantitative.s129.e1" id="quantitative.s129.p0" /></sentence><sentence id="quantitative.s130" text="There was no significant pharmacokinetic interaction between fluconazole and azithromycin"><entity charOffset="77-88" id="quantitative.s130.e0" text="azithromycin" type="active-ingredient" /><entity charOffset="61-71" id="quantitative.s130.e1" text="fluconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s130.e0" e2="quantitative.s130.e1" id="quantitative.s130.p0" /></sentence><sentence id="quantitative.s131" text="There was no significant pharmacokinetic interaction between fluconazole and azithromycin"><entity charOffset="77-88" id="quantitative.s131.e0" text="azithromycin" type="active-ingredient" /><entity charOffset="61-71" id="quantitative.s131.e1" text="fluconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s131.e0" e2="quantitative.s131.e1" id="quantitative.s131.p0" /></sentence><sentence id="quantitative.s132" text="On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively"><entity charOffset="28-38" id="quantitative.s132.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="54-62" id="quantitative.s132.e1" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s132.e0" e2="quantitative.s132.e1" id="quantitative.s132.p0" /></sentence><sentence id="quantitative.s133" text="On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively"><entity charOffset="28-38" id="quantitative.s133.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="54-62" id="quantitative.s133.e1" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s133.e0" e2="quantitative.s133.e1" id="quantitative.s133.p0" /></sentence><sentence id="quantitative.s134" text="Fluconazole reduced the clearance of IV midazolam by 51%"><entity charOffset="0-10" id="quantitative.s134.e0" text="Fluconazole" type="active-ingredient" /><entity charOffset="40-48" id="quantitative.s134.e1" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s134.e0" e2="quantitative.s134.e1" id="quantitative.s134.p0" /></sentence><sentence id="quantitative.s135" text="The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean ± SD increase in AUC of 44% ± 29% (range: -13 to 115%) and Cmax increased 19% ± 19% (range: -23 to 62%)"><entity charOffset="20-28" id="quantitative.s135.e0" text="glyburide" type="active-ingredient" /><entity charOffset="110-120" id="quantitative.s135.e1" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s135.e0" e2="quantitative.s135.e1" id="quantitative.s135.p0" /></sentence><sentence id="quantitative.s136" text="The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean ± SD increase in AUC of 49% ± 13% (range: 27 to 73%) and an increase in Cmax of 19% ± 23% (range: -11 to 79%)."><entity charOffset="112-122" id="quantitative.s136.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s136.e1" text="glipizide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s136.e0" e2="quantitative.s136.e1" id="quantitative.s136.p0" /></sentence><sentence id="quantitative.s137" text="In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%)."><entity charOffset="142-152" id="quantitative.s137.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="64-74" id="quantitative.s137.e1" text="Tolbutamide" type="active-ingredient" /><entity charOffset="190-200" id="quantitative.s137.e2" text="Tolbutamide" type="active-ingredient" /><entity charOffset="239-249" id="quantitative.s137.e3" text="Tolbutamide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s137.e0" e2="quantitative.s137.e3" id="quantitative.s137.p0" /></sentence><sentence id="quantitative.s138" text="The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours."><entity charOffset="155-165" id="quantitative.s138.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="24-35" id="quantitative.s138.e1" text="theophylline" type="active-ingredient" /><entity charOffset="258-269" id="quantitative.s138.e2" text="theophylline" type="active-ingredient" /><entity charOffset="355-366" id="quantitative.s138.e3" text="theophylline" type="active-ingredient" /><entity charOffset="464-475" id="quantitative.s138.e4" text="theophylline" type="active-ingredient" /><entity charOffset="546-557" id="quantitative.s138.e5" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s138.e0" e2="quantitative.s138.e5" id="quantitative.s138.p0" /></sentence><sentence id="quantitative.s139" text="There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%)"><entity charOffset="177-187" id="quantitative.s139.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="36-47" id="quantitative.s139.e1" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s139.e0" e2="quantitative.s139.e1" id="quantitative.s139.p0" /></sentence><sentence id="quantitative.s140" text="Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%)."><entity charOffset="186-196" id="quantitative.s140.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="204-214" id="quantitative.s140.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="0-8" id="quantitative.s140.e2" text="Phenytoin" type="active-ingredient" /><entity charOffset="45-53" id="quantitative.s140.e3" text="Phenytoin" type="active-ingredient" /><entity charOffset="308-316" id="quantitative.s140.e4" text="Phenytoin" type="active-ingredient" /><entity charOffset="350-358" id="quantitative.s140.e5" text="Phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s140.e1" e2="quantitative.s140.e5" id="quantitative.s140.p0" /></sentence><sentence id="quantitative.s141" text="However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers."><entity charOffset="158-168" id="quantitative.s141.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="236-246" id="quantitative.s141.e1" text="fluconazole" type="active-ingredient" /><entity charOffset="31-40" id="quantitative.s141.e2" text="cimetidine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s141.e1" e2="quantitative.s141.e2" id="quantitative.s141.p0" /></sentence><sentence id="quantitative.s142" text="In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo."><entity charOffset="208-224" id="quantitative.s142.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="297-313" id="quantitative.s142.e1" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="141-151" id="quantitative.s142.e2" text="fluconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s142.e1" e2="quantitative.s142.e2" id="quantitative.s142.p0" /></sentence><sentence id="quantitative.s143" text="In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo."><entity charOffset="141-151" id="quantitative.s143.e0" text="fluconazole" type="active-ingredient" /><entity charOffset="230-242" id="quantitative.s143.e1" text="norethindrone" type="active-ingredient" /><entity charOffset="319-331" id="quantitative.s143.e2" text="norethindrone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s143.e0" e2="quantitative.s143.e2" id="quantitative.s143.p0" /></sentence><sentence id="quantitative.s144" text="In a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together"><entity charOffset="139-148" id="quantitative.s144.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="311-320" id="quantitative.s144.e1" text="omeprazole" type="active-ingredient" /><entity charOffset="69-74" id="quantitative.s144.e2" text="Plavix" type="drug-product" /><entity charOffset="177-182" id="quantitative.s144.e3" text="Plavix" type="drug-product" /><entity charOffset="300-305" id="quantitative.s144.e4" text="Plavix" type="drug-product" /><pair ddi="true" e1="quantitative.s144.e1" e2="quantitative.s144.e4" id="quantitative.s144.p0" /></sentence><sentence id="quantitative.s145" text="Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis"><entity charOffset="31-41" id="quantitative.s145.e0" text="clopidogrel" type="active-ingredient" /><entity charOffset="98-105" id="quantitative.s145.e1" text="warfarin" type="active-ingredient" /><entity charOffset="167-174" id="quantitative.s145.e2" text="warfarin" type="active-ingredient" /><entity charOffset="217-224" id="quantitative.s145.e3" text="warfarin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s145.e0" e2="quantitative.s145.e3" id="quantitative.s145.p0" /></sentence><sentence id="quantitative.s146" text="Voriconazole Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). "><entity charOffset="146-154" id="quantitative.s146.e0" text="methadone" type="active-ingredient" /><entity charOffset="210-218" id="quantitative.s146.e1" text="methadone" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s146.e2" text="voriconazole" type="active-ingredient" /><entity charOffset="48-59" id="quantitative.s146.e3" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s146.e1" e2="quantitative.s146.e3" id="quantitative.s146.p0" /></sentence><sentence id="quantitative.s147" text="In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently"><entity charOffset="44-52" id="quantitative.s147.e0" text="methadone" type="active-ingredient" /><entity charOffset="220-228" id="quantitative.s147.e1" text="methadone" type="active-ingredient" /><entity charOffset="75-83" id="quantitative.s147.e2" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s147.e1" e2="quantitative.s147.e2" id="quantitative.s147.p0" /></sentence><sentence id="quantitative.s148" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients"><entity charOffset="237-246" id="quantitative.s148.e0" text="lamivudine" type="active-ingredient" /><entity charOffset="223-231" id="quantitative.s148.e1" text="ribavirin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s148.e0" e2="quantitative.s148.e1" id="quantitative.s148.p0" /></sentence><sentence id="quantitative.s149" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients"><entity charOffset="223-231" id="quantitative.s149.e0" text="ribavirin" type="active-ingredient" /><entity charOffset="258-266" id="quantitative.s149.e1" text="stavudine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s149.e0" e2="quantitative.s149.e1" id="quantitative.s149.p0" /></sentence><sentence id="quantitative.s150" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients "><entity charOffset="223-231" id="quantitative.s150.e0" text="ribavirin" type="active-ingredient" /><entity charOffset="281-290" id="quantitative.s150.e1" text="zidovudine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s150.e0" e2="quantitative.s150.e1" id="quantitative.s150.p0" /></sentence><sentence id="quantitative.s151" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin"><entity charOffset="111-119" id="quantitative.s151.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="215-223" id="quantitative.s151.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="304-312" id="quantitative.s151.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="400-408" id="quantitative.s151.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="156-165" id="quantitative.s151.e4" text="zidovudine" type="active-ingredient" /><entity charOffset="317-326" id="quantitative.s151.e5" text="zidovudine" type="active-ingredient" /><entity charOffset="361-370" id="quantitative.s151.e6" text="zidovudine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s151.e3" e2="quantitative.s151.e6" id="quantitative.s151.p0" /></sentence><sentence id="quantitative.s152" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed"><entity charOffset="111-119" id="quantitative.s152.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="215-223" id="quantitative.s152.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="156-165" id="quantitative.s152.e2" text="zidovudine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s152.e1" e2="quantitative.s152.e2" id="quantitative.s152.p0" /></sentence><sentence id="quantitative.s153" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%"><entity charOffset="43-53" id="quantitative.s153.e0" text="propafenone" type="active-ingredient" /><entity charOffset="120-130" id="quantitative.s153.e1" text="propafenone" type="active-ingredient" /><entity charOffset="176-186" id="quantitative.s153.e2" text="propafenone" type="active-ingredient" /><entity charOffset="30-37" id="quantitative.s153.e3" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s153.e2" e2="quantitative.s153.e3" id="quantitative.s153.p0" /></sentence><sentence id="quantitative.s154" text="Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone"><entity charOffset="30-40" id="quantitative.s154.e0" text="propafenone" type="active-ingredient" /><entity charOffset="174-184" id="quantitative.s154.e1" text="propafenone" type="active-ingredient" /><entity charOffset="72-81" id="quantitative.s154.e2" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s154.e1" e2="quantitative.s154.e2" id="quantitative.s154.p0" /></sentence><sentence id="quantitative.s155" text="No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients"><entity charOffset="50-60" id="quantitative.s155.e0" text="propafenone" type="active-ingredient" /><entity charOffset="65-73" id="quantitative.s155.e1" text="lidocaine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s155.e0" e2="quantitative.s155.e1" id="quantitative.s155.p0" /></sentence><sentence id="quantitative.s156" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol"><entity charOffset="24-34" id="quantitative.s156.e0" text="propafenone" type="active-ingredient" /><entity charOffset="102-111" id="quantitative.s156.e1" text="metoprolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s156.e0" e2="quantitative.s156.e1" id="quantitative.s156.p0" /></sentence><sentence id="quantitative.s157" text="In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%"><entity charOffset="33-42" id="quantitative.s157.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="75-84" id="quantitative.s157.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="49-59" id="quantitative.s157.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s157.e1" e2="quantitative.s157.e2" id="quantitative.s157.p0" /></sentence><sentence id="quantitative.s158" text="Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%"><entity charOffset="35-45" id="quantitative.s158.e0" text="propranolol" type="active-ingredient" /><entity charOffset="77-87" id="quantitative.s158.e1" text="propranolol" type="active-ingredient" /><entity charOffset="19-29" id="quantitative.s158.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s158.e1" e2="quantitative.s158.e2" id="quantitative.s158.p0" /></sentence><sentence id="quantitative.s159" text="Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%"><entity charOffset="46-55" id="quantitative.s159.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s159.e1" text="propafenone" type="active-ingredient" /><entity charOffset="99-109" id="quantitative.s159.e2" text="propafenone" type="active-ingredient" /><entity charOffset="148-158" id="quantitative.s159.e3" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s159.e0" e2="quantitative.s159.e3" id="quantitative.s159.p0" /></sentence><sentence id="quantitative.s160" text="No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients"><entity charOffset="50-60" id="quantitative.s160.e0" text="propafenone" type="active-ingredient" /><entity charOffset="65-73" id="quantitative.s160.e1" text="lidocaine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s160.e0" e2="quantitative.s160.e1" id="quantitative.s160.p0" /></sentence><sentence id="quantitative.s161" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%"><entity charOffset="30-37" id="quantitative.s161.e0" text="rifampin" type="active-ingredient" /><entity charOffset="172-186" id="quantitative.s161.e1" text="5OH-propafenone" type="metabolite" /><pair ddi="true" e1="quantitative.s161.e0" e2="quantitative.s161.e1" id="quantitative.s161.p0" /></sentence><sentence id="quantitative.s162" text="A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold"><entity charOffset="17-25" id="quantitative.s162.e0" text="quinidine" type="active-ingredient" /><entity charOffset="68-78" id="quantitative.s162.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s162.e0" e2="quantitative.s162.e1" id="quantitative.s162.p0" /></sentence><sentence id="quantitative.s163" text="The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol"><entity charOffset="87-97" id="quantitative.s163.e0" text="propranolol" type="active-ingredient" /><entity charOffset="24-34" id="quantitative.s163.e1" text="propafenone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s163.e0" e2="quantitative.s163.e1" id="quantitative.s163.p0" /></sentence><sentence id="quantitative.s164" text="Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone."><entity charOffset="30-38" id="quantitative.s164.e0" text="quinidine" type="active-ingredient" /><entity charOffset="96-106" id="quantitative.s164.e1" text="propafenone" type="active-ingredient" /><entity charOffset="153-163" id="quantitative.s164.e2" text="propafenone" type="active-ingredient" /><entity charOffset="264-274" id="quantitative.s164.e3" text="propafenone" type="active-ingredient" /><entity charOffset="303-313" id="quantitative.s164.e4" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s164.e0" e2="quantitative.s164.e4" id="quantitative.s164.p0" /></sentence><sentence id="quantitative.s165" text="The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. "><entity charOffset="50-57" id="quantitative.s165.e0" text="warfarin" type="active-ingredient" /><entity charOffset="69-76" id="quantitative.s165.e1" text="warfarin" type="active-ingredient" /><entity charOffset="204-211" id="quantitative.s165.e2" text="warfarin" type="active-ingredient" /><entity charOffset="34-44" id="quantitative.s165.e3" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s165.e2" e2="quantitative.s165.e3" id="quantitative.s165.p0" /></sentence><sentence id="quantitative.s166" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%"><entity charOffset="172-186" id="quantitative.s166.e0" text="5OH-propafenone" type="metabolite" /><entity charOffset="640-654" id="quantitative.s166.e1" text="5OH-propafenone" type="metabolite" /><entity charOffset="30-37" id="quantitative.s166.e2" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s166.e1" e2="quantitative.s166.e2" id="quantitative.s166.p0" /></sentence><sentence id="quantitative.s167" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively"><entity charOffset="43-53" id="quantitative.s167.e0" text="propafenone" type="active-ingredient" /><entity charOffset="120-130" id="quantitative.s167.e1" text="propafenone" type="active-ingredient" /><entity charOffset="176-186" id="quantitative.s167.e2" text="propafenone" type="active-ingredient" /><entity charOffset="221-231" id="quantitative.s167.e3" text="propafenone" type="active-ingredient" /><entity charOffset="301-311" id="quantitative.s167.e4" text="propafenone" type="active-ingredient" /><entity charOffset="372-382" id="quantitative.s167.e5" text="propafenone" type="active-ingredient" /><entity charOffset="30-37" id="quantitative.s167.e6" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s167.e5" e2="quantitative.s167.e6" id="quantitative.s167.p0" /></sentence><sentence id="quantitative.s168" text="Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%"><entity charOffset="19-29" id="quantitative.s168.e0" text="propafenone" type="active-ingredient" /><entity charOffset="35-41" id="quantitative.s168.e1" text="digoxin" type="active-ingredient" /><entity charOffset="72-78" id="quantitative.s168.e2" text="digoxin" type="active-ingredient" /><entity charOffset="153-159" id="quantitative.s168.e3" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s168.e0" e2="quantitative.s168.e3" id="quantitative.s168.p0" /></sentence><sentence id="quantitative.s169" text="Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone"><entity charOffset="299-313" id="quantitative.s169.e0" text="5OH-propafenone" type="metabolite" /><entity charOffset="30-38" id="quantitative.s169.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s169.e0" e2="quantitative.s169.e1" id="quantitative.s169.p0" /></sentence><sentence id="quantitative.s170" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%"><entity charOffset="30-37" id="quantitative.s170.e0" text="rifampin" type="active-ingredient" /><entity charOffset="43-53" id="quantitative.s170.e1" text="propafenone" type="active-ingredient" /><entity charOffset="120-130" id="quantitative.s170.e2" text="propafenone" type="active-ingredient" /><entity charOffset="176-186" id="quantitative.s170.e3" text="propafenone" type="active-ingredient" /><entity charOffset="221-231" id="quantitative.s170.e4" text="propafenone" type="active-ingredient" /><entity charOffset="301-311" id="quantitative.s170.e5" text="propafenone" type="active-ingredient" /><entity charOffset="372-382" id="quantitative.s170.e6" text="propafenone" type="active-ingredient" /><entity charOffset="434-444" id="quantitative.s170.e7" text="propafenone" type="active-ingredient" /><entity charOffset="561-571" id="quantitative.s170.e8" text="propafenone" type="active-ingredient" /><entity charOffset="644-654" id="quantitative.s170.e9" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s170.e0" e2="quantitative.s170.e9" id="quantitative.s170.p0" /></sentence><sentence id="quantitative.s171" text="Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%"><entity charOffset="218-231" id="quantitative.s171.e0" text="norpropafenone" type="metabolite" /><entity charOffset="30-37" id="quantitative.s171.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s171.e0" e2="quantitative.s171.e1" id="quantitative.s171.p0" /></sentence><sentence id="quantitative.s172" text="Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM"><entity charOffset="30-38" id="quantitative.s172.e0" text="quinidine" type="active-ingredient" /><entity charOffset="78-106" id="quantitative.s172.e1" text="immediate-release propafenone" type="drug-product" /><pair ddi="true" e1="quantitative.s172.e0" e2="quantitative.s172.e1" id="quantitative.s172.p0" /></sentence><sentence id="quantitative.s173" text="Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels"><entity charOffset="30-40" id="quantitative.s173.e0" text="fluvastatin" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s173.e1" text="fluvastatin" type="active-ingredient" /><entity charOffset="54-65" id="quantitative.s173.e2" text="itraconazole" type="active-ingredient" /><entity charOffset="114-125" id="quantitative.s173.e3" text="itraconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s173.e1" e2="quantitative.s173.e3" id="quantitative.s173.p0" /></sentence><sentence id="quantitative.s174" text="Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels"><entity charOffset="30-40" id="quantitative.s174.e0" text="fluvastatin" type="active-ingredient" /><entity charOffset="130-140" id="quantitative.s174.e1" text="fluvastatin" type="active-ingredient" /><entity charOffset="54-65" id="quantitative.s174.e2" text="itraconazole" type="active-ingredient" /><entity charOffset="114-125" id="quantitative.s174.e3" text="itraconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s174.e1" e2="quantitative.s174.e3" id="quantitative.s174.p0" /></sentence><sentence id="quantitative.s175" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance"><entity charOffset="70-79" id="quantitative.s175.e0" text="sertraline" type="active-ingredient" /><entity charOffset="158-164" id="quantitative.s175.e1" text="digoxin" type="active-ingredient" /><entity charOffset="176-182" id="quantitative.s175.e2" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s175.e0" e2="quantitative.s175.e2" id="quantitative.s175.p0" /></sentence><sentence id="quantitative.s176" text="In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval."><entity charOffset="35-44" id="quantitative.s176.e0" text="atazanavir" type="active-ingredient" /><entity charOffset="68-76" id="quantitative.s176.e1" text="diltiazem" type="active-ingredient" /><entity charOffset="151-159" id="quantitative.s176.e2" text="diltiazem" type="active-ingredient" /><pair ddi="true" e1="quantitative.s176.e0" e2="quantitative.s176.e2" id="quantitative.s176.p0" /></sentence><sentence id="quantitative.s177" text="In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. ["><entity charOffset="35-44" id="quantitative.s177.e0" text="atazanavir" type="active-ingredient" /><entity charOffset="139-148" id="quantitative.s177.e1" text="atazanavir" type="active-ingredient" /><entity charOffset="68-75" id="quantitative.s177.e2" text="atenolol" type="active-ingredient" /><entity charOffset="154-161" id="quantitative.s177.e3" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s177.e1" e2="quantitative.s177.e3" id="quantitative.s177.p0" /></sentence><sentence id="quantitative.s178" text="Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL"><entity charOffset="122-128" id="quantitative.s178.e0" text="digoxin" type="active-ingredient" /><entity charOffset="20-30" id="quantitative.s178.e1" text="simvastatin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s178.e0" e2="quantitative.s178.e1" id="quantitative.s178.p0" /></sentence><sentence id="quantitative.s179" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. "><entity charOffset="174-185" id="quantitative.s179.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="37-47" id="quantitative.s179.e1" text="simvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s179.e0" e2="quantitative.s179.e1" id="quantitative.s179.p0" /></sentence><sentence id="quantitative.s180" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. "><entity charOffset="160-168" id="quantitative.s180.e0" text="midazolam" type="active-ingredient" /><entity charOffset="37-47" id="quantitative.s180.e1" text="simvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s180.e0" e2="quantitative.s180.e1" id="quantitative.s180.p0" /></sentence><sentence id="quantitative.s181" text="In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate."><entity charOffset="210-217" id="quantitative.s181.e0" text="naproxen" type="active-ingredient" /><entity charOffset="350-371" id="quantitative.s181.e1" text="7-hydroxymethotrexate." type="metabolite" /><pair ddi="false" e1="quantitative.s181.e0" e2="quantitative.s181.e1" id="quantitative.s181.p0" /></sentence><sentence id="quantitative.s182" text=" In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate."><entity charOffset="44-80" id="quantitative.s182.e0" text="lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="156-165" id="quantitative.s182.e1" text="sucralfate" type="active-ingredient" /><entity charOffset="333-342" id="quantitative.s182.e2" text="sucralfate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s182.e0" e2="quantitative.s182.e2" id="quantitative.s182.p0" /></sentence><sentence id="quantitative.s183" text="In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. "><entity charOffset="155-164" id="quantitative.s183.e0" text="sucralfate" type="active-ingredient" /><entity charOffset="332-341" id="quantitative.s183.e1" text="sucralfate" type="active-ingredient" /><entity charOffset="91-100" id="quantitative.s183.e2" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s183.e1" e2="quantitative.s183.e2" id="quantitative.s183.p0" /></sentence><sentence id="quantitative.s184" text="In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate."><entity charOffset="242-278" id="quantitative.s184.e0" text="lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="350-371" id="quantitative.s184.e1" text="7-hydroxymethotrexate." type="metabolite" /><pair ddi="false" e1="quantitative.s184.e0" e2="quantitative.s184.e1" id="quantitative.s184.p0" /></sentence><sentence id="quantitative.s185" text="When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. "><entity charOffset="5-41" id="quantitative.s185.e0" text="lansoprazole delayed-release capsules" type="drug-product" /><entity charOffset="80-91" id="quantitative.s185.e1" text="theophylline" type="active-ingredient" /><entity charOffset="153-164" id="quantitative.s185.e2" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s185.e0" e2="quantitative.s185.e2" id="quantitative.s185.p0" /></sentence><sentence id="quantitative.s186" text="In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate"><entity charOffset="154-165" id="quantitative.s186.e0" text="methotrexate" type="active-ingredient" /><entity charOffset="333-344" id="quantitative.s186.e1" text="methotrexate" type="active-ingredient" /><entity charOffset="359-370" id="quantitative.s186.e2" text="methotrexate" type="active-ingredient" /><entity charOffset="210-217" id="quantitative.s186.e3" text="naproxen" type="active-ingredient" /><pair ddi="false" e1="quantitative.s186.e2" e2="quantitative.s186.e3" id="quantitative.s186.p0" /></sentence><sentence id="quantitative.s187" text="In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate."><entity charOffset="154-165" id="quantitative.s187.e0" text="methotrexate" type="active-ingredient" /><entity charOffset="333-344" id="quantitative.s187.e1" text="methotrexate" type="active-ingredient" /><entity charOffset="359-370" id="quantitative.s187.e2" text="methotrexate" type="active-ingredient" /><entity charOffset="242-278" id="quantitative.s187.e3" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="false" e1="quantitative.s187.e2" e2="quantitative.s187.e3" id="quantitative.s187.p0" /></sentence><sentence id="quantitative.s188" text="In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin "><entity charOffset="129-136" id="quantitative.s188.e0" text="warfarin" type="active-ingredient" /><entity charOffset="177-184" id="quantitative.s188.e1" text="warfarin" type="active-ingredient" /><entity charOffset="87-123" id="quantitative.s188.e2" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="false" e1="quantitative.s188.e1" e2="quantitative.s188.e2" id="quantitative.s188.p0" /></sentence><sentence id="quantitative.s189" text="A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline"><entity charOffset="43-54" id="quantitative.s189.e0" text="theophylline" type="active-ingredient" /><entity charOffset="158-169" id="quantitative.s189.e1" text="theophylline" type="active-ingredient" /><entity charOffset="101-137" id="quantitative.s189.e2" text="lansoprazole delayed-release capsules" type="drug-product" /><pair ddi="true" e1="quantitative.s189.e1" e2="quantitative.s189.e2" id="quantitative.s189.p0" /></sentence><sentence id="quantitative.s190" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. "><entity charOffset="47-53" id="quantitative.s190.e0" text="digoxin" type="active-ingredient" /><entity charOffset="218-224" id="quantitative.s190.e1" text="digoxin" type="active-ingredient" /><entity charOffset="8-16" id="quantitative.s190.e2" text="verapamil" type="active-ingredient" /><entity charOffset="205-213" id="quantitative.s190.e3" text="verapamil" type="active-ingredient" /><entity charOffset="257-265" id="quantitative.s190.e4" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s190.e1" e2="quantitative.s190.e4" id="quantitative.s190.p0" /></sentence><sentence id="quantitative.s191" text="Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL. Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly. Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration. "><entity charOffset="96-105" id="quantitative.s191.e0" text="nelfinavir" type="active-ingredient" /><entity charOffset="440-449" id="quantitative.s191.e1" text="nelfinavir" type="active-ingredient" /><entity charOffset="80-89" id="quantitative.s191.e2" text="tacrolimus" type="active-ingredient" /><entity charOffset="141-150" id="quantitative.s191.e3" text="tacrolimus" type="active-ingredient" /><entity charOffset="203-212" id="quantitative.s191.e4" text="tacrolimus" type="active-ingredient" /><entity charOffset="279-288" id="quantitative.s191.e5" text="tacrolimus" type="active-ingredient" /><entity charOffset="354-363" id="quantitative.s191.e6" text="tacrolimus" type="active-ingredient" /><entity charOffset="474-483" id="quantitative.s191.e7" text="tacrolimus" type="active-ingredient" /><pair ddi="true" e1="quantitative.s191.e1" e2="quantitative.s191.e7" id="quantitative.s191.p0" /></sentence><sentence id="quantitative.s192" text="In addition, there was a significant increase in tacrolimus clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin administration"><entity charOffset="49-58" id="quantitative.s192.e0" text="tacrolimus" type="active-ingredient" /><entity charOffset="135-142" id="quantitative.s192.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s192.e0" e2="quantitative.s192.e1" id="quantitative.s192.p0" /></sentence><sentence id="quantitative.s193" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide"><entity charOffset="24-33" id="quantitative.s193.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="76-85" id="quantitative.s193.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s193.e0" e2="quantitative.s193.e1" id="quantitative.s193.p0" /></sentence><sentence id="quantitative.s194" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics"><entity charOffset="26-44" id="quantitative.s194.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="63-72" id="quantitative.s194.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s194.e0" e2="quantitative.s194.e1" id="quantitative.s194.p0" /></sentence><sentence id="quantitative.s195" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide"><entity charOffset="90-108" id="quantitative.s195.e0" text="hydrochlorothiazide" type="active-ingredient" /><entity charOffset="24-33" id="quantitative.s195.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s195.e0" e2="quantitative.s195.e1" id="quantitative.s195.p0" /></sentence><sentence id="quantitative.s196" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics"><entity charOffset="12-21" id="quantitative.s196.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="63-72" id="quantitative.s196.e1" text="irbesartan" type="active-ingredient" /><pair ddi="false" e1="quantitative.s196.e0" e2="quantitative.s196.e1" id="quantitative.s196.p0" /></sentence><sentence id="quantitative.s197" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose"><entity charOffset="220-230" id="quantitative.s197.e0" text="tolbutamide" type="active-ingredient" /><entity charOffset="70-79" id="quantitative.s197.e1" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s197.e0" e2="quantitative.s197.e1" id="quantitative.s197.p0" /></sentence><sentence id="quantitative.s198" text="Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug"><entity charOffset="0-9" id="quantitative.s198.e0" text="Sertraline" type="active-ingredient" /><entity charOffset="128-138" id="quantitative.s198.e1" text="tolbutamide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s198.e0" e2="quantitative.s198.e1" id="quantitative.s198.p0" /></sentence><sentence id="quantitative.s199" text="The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride."><entity charOffset="128-136" id="quantitative.s199.e0" text="cisapride" type="active-ingredient" /><entity charOffset="44-53" id="quantitative.s199.e1" text="sertraline" type="active-ingredient" /><pair ddi="false" e1="quantitative.s199.e0" e2="quantitative.s199.e1" id="quantitative.s199.p0" /></sentence><sentence id="quantitative.s200" text="The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride."><entity charOffset="44-53" id="quantitative.s200.e0" text="sertraline" type="active-ingredient" /><entity charOffset="97-107" id="quantitative.s200.e1" text="terfenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s200.e0" e2="quantitative.s200.e1" id="quantitative.s200.p0" /></sentence><sentence id="quantitative.s201" text="The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride"><entity charOffset="44-53" id="quantitative.s201.e0" text="sertraline" type="active-ingredient" /><entity charOffset="110-122" id="quantitative.s201.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s201.e0" e2="quantitative.s201.e1" id="quantitative.s201.p0" /></sentence><sentence id="quantitative.s202" text="Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%)."><entity charOffset="62-71" id="quantitative.s202.e0" text="sertraline" type="active-ingredient" /><entity charOffset="38-46" id="quantitative.s202.e1" text="cisapride" type="active-ingredient" /><entity charOffset="113-121" id="quantitative.s202.e2" text="cisapride" type="active-ingredient" /><entity charOffset="124-132" id="quantitative.s202.e3" text="cisapride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s202.e0" e2="quantitative.s202.e3" id="quantitative.s202.p0" /></sentence><sentence id="quantitative.s203" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels"><entity charOffset="32-38" id="quantitative.s203.e0" text="digoxin" type="active-ingredient" /><entity charOffset="205-211" id="quantitative.s203.e1" text="digoxin" type="active-ingredient" /><entity charOffset="0-9" id="quantitative.s203.e2" text="Mexiletine" type="active-ingredient" /><entity charOffset="133-142" id="quantitative.s203.e3" text="Mexiletine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s203.e1" e2="quantitative.s203.e3" id="quantitative.s203.p0" /></sentence><sentence id="quantitative.s204" text="In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2"><entity charOffset="74-83" id="quantitative.s204.e0" text="mexiletine" type="active-ingredient" /><entity charOffset="140-150" id="quantitative.s204.e1" text="fluvoxamine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s204.e0" e2="quantitative.s204.e1" id="quantitative.s204.p0" /></sentence><sentence id="quantitative.s205" text="In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine"><entity charOffset="62-72" id="quantitative.s205.e0" text="propafenone" type="active-ingredient" /><entity charOffset="137-146" id="quantitative.s205.e1" text="mexiletine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s205.e0" e2="quantitative.s205.e1" id="quantitative.s205.p0" /></sentence><sentence id="quantitative.s206" text="In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group"><entity charOffset="101-111" id="quantitative.s206.e0" text="propafenone" type="active-ingredient" /><entity charOffset="143-152" id="quantitative.s206.e1" text="mexiletine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s206.e0" e2="quantitative.s206.e1" id="quantitative.s206.p0" /></sentence><sentence id="quantitative.s207" text="In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable"><entity charOffset="143-152" id="quantitative.s207.e0" text="mexiletine" type="active-ingredient" /><entity charOffset="228-237" id="quantitative.s207.e1" text="mexiletine" type="active-ingredient" /><entity charOffset="101-111" id="quantitative.s207.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s207.e1" e2="quantitative.s207.e2" id="quantitative.s207.p0" /></sentence><sentence id="quantitative.s208" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="95-101" id="quantitative.s208.e0" text="digoxin" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s208.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s208.e0" e2="quantitative.s208.e1" id="quantitative.s208.p0" /></sentence><sentence id="quantitative.s209" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="83-92" id="quantitative.s209.e0" text="lovastatin" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s209.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s209.e0" e2="quantitative.s209.e1" id="quantitative.s209.p0" /></sentence><sentence id="quantitative.s210" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="20-28" id="quantitative.s210.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="149-156" id="quantitative.s210.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s210.e0" e2="quantitative.s210.e1" id="quantitative.s210.p0" /></sentence><sentence id="quantitative.s211" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="20-28" id="quantitative.s211.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="173-180" id="quantitative.s211.e1" text="ramipril" type="active-ingredient" /><pair ddi="false" e1="quantitative.s211.e0" e2="quantitative.s211.e1" id="quantitative.s211.p0" /></sentence><sentence id="quantitative.s212" text="Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren"><entity charOffset="0-11" id="quantitative.s212.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="53-64" id="quantitative.s212.e1" text="ketoconazole" type="active-ingredient" /><entity charOffset="71-79" id="quantitative.s212.e2" text="aliskiren" type="active-ingredient" /><entity charOffset="141-149" id="quantitative.s212.e3" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s212.e1" e2="quantitative.s212.e3" id="quantitative.s212.p0" /></sentence><sentence id="quantitative.s213" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="115-124" id="quantitative.s213.e0" text="amlodipine" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s213.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s213.e0" e2="quantitative.s213.e1" id="quantitative.s213.p0" /></sentence><sentence id="quantitative.s214" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="104-112" id="quantitative.s214.e0" text="valsartan" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s214.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s214.e0" e2="quantitative.s214.e1" id="quantitative.s214.p0" /></sentence><sentence id="quantitative.s215" text="Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing"><entity charOffset="0-11" id="quantitative.s215.e0" text="atorvastatin" type="active-ingredient" /><entity charOffset="34-45" id="quantitative.s215.e1" text="atorvastatin" type="active-ingredient" /><entity charOffset="83-91" id="quantitative.s215.e2" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s215.e1" e2="quantitative.s215.e2" id="quantitative.s215.p0" /></sentence><sentence id="quantitative.s216" text="Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing"><entity charOffset="0-9" id="quantitative.s216.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="32-41" id="quantitative.s216.e1" text="irbesartan" type="active-ingredient" /><pair ddi="true" e1="quantitative.s216.e1" e2="quantitative.s216.e1" id="quantitative.s216.p0" /></sentence><sentence id="quantitative.s217" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="20-28" id="quantitative.s217.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="138-146" id="quantitative.s217.e1" text="celecoxib" type="active-ingredient" /><pair ddi="false" e1="quantitative.s217.e0" e2="quantitative.s217.e1" id="quantitative.s217.p0" /></sentence><sentence id="quantitative.s218" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="127-135" id="quantitative.s218.e0" text="metformin" type="active-ingredient" /><entity charOffset="20-28" id="quantitative.s218.e1" text="aliskiren" type="active-ingredient" /><pair ddi="false" e1="quantitative.s218.e0" e2="quantitative.s218.e1" id="quantitative.s218.p0" /></sentence><sentence id="quantitative.s219" text="Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren"><entity charOffset="0-8" id="quantitative.s219.e0" text="verapamil" type="active-ingredient" /><entity charOffset="41-49" id="quantitative.s219.e1" text="verapamil" type="active-ingredient" /><entity charOffset="63-71" id="quantitative.s219.e2" text="aliskiren" type="active-ingredient" /><entity charOffset="137-145" id="quantitative.s219.e3" text="aliskiren" type="active-ingredient" /><pair ddi="true" e1="quantitative.s219.e1" e2="quantitative.s219.e3" id="quantitative.s219.p0" /></sentence><sentence id="quantitative.s220" text="When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively"><entity charOffset="5-13" id="quantitative.s220.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="39-48" id="quantitative.s220.e1" text="furosemide" type="active-ingredient" /><entity charOffset="71-80" id="quantitative.s220.e2" text="furosemide" type="active-ingredient" /><pair ddi="true" e1="quantitative.s220.e0" e2="quantitative.s220.e2" id="quantitative.s220.p0" /></sentence><sentence id="quantitative.s221" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="20-28" id="quantitative.s221.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="159-170" id="quantitative.s221.e1" text="atorvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s221.e0" e2="quantitative.s221.e1" id="quantitative.s221.p0" /></sentence><sentence id="quantitative.s222" text="Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide"><entity charOffset="20-28" id="quantitative.s222.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="185-203" id="quantitative.s222.e1" text="hydrochlorothiazide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s222.e0" e2="quantitative.s222.e1" id="quantitative.s222.p0" /></sentence><sentence id="quantitative.s223" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren"><entity charOffset="76-84" id="quantitative.s223.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="171-179" id="quantitative.s223.e1" text="aliskiren" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s223.e2" text="cyclosporine" type="active-ingredient" /><entity charOffset="52-63" id="quantitative.s223.e3" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s223.e1" e2="quantitative.s223.e3" id="quantitative.s223.p0" /></sentence><sentence id="quantitative.s224" text="Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren"><entity charOffset="66-74" id="quantitative.s224.e0" text="aliskiren" type="active-ingredient" /><entity charOffset="160-168" id="quantitative.s224.e1" text="aliskiren" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s224.e2" text="itraconazole" type="active-ingredient" /><entity charOffset="41-52" id="quantitative.s224.e3" text="itraconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s224.e1" e2="quantitative.s224.e3" id="quantitative.s224.p0" /></sentence><sentence id="quantitative.s225" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg)"><entity charOffset="0-9" id="quantitative.s225.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="99-112" id="quantitative.s225.e1" text="levonorgestrel" type="active-ingredient" /><pair ddi="false" e1="quantitative.s225.e0" e2="quantitative.s225.e1" id="quantitative.s225.p0" /></sentence><sentence id="quantitative.s226" text="Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin"><entity charOffset="54-63" id="quantitative.s226.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="137-146" id="quantitative.s226.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="79-90" id="quantitative.s226.e2" text="atorvastatin" type="active-ingredient" /><entity charOffset="151-162" id="quantitative.s226.e3" text="atorvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s226.e1" e2="quantitative.s226.e3" id="quantitative.s226.p0" /></sentence><sentence id="quantitative.s227" text="Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil"><entity charOffset="51-67" id="quantitative.s227.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="143-152" id="quantitative.s227.e1" text="sildenafil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s227.e0" e2="quantitative.s227.e1" id="quantitative.s227.p0" /></sentence><sentence id="quantitative.s228" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg)"><entity charOffset="0-9" id="quantitative.s228.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="70-86" id="quantitative.s228.e1" text="ethinyl estradiol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s228.e0" e2="quantitative.s228.e1" id="quantitative.s228.p0" /></sentence><sentence id="quantitative.s229" text="Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil"><entity charOffset="80-93" id="quantitative.s229.e0" text="levonorgestrel" type="active-ingredient" /><entity charOffset="143-152" id="quantitative.s229.e1" text="sildenafil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s229.e0" e2="quantitative.s229.e1" id="quantitative.s229.p0" /></sentence><sentence id="quantitative.s230" text="When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC)"><entity charOffset="65-76" id="quantitative.s230.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="29-38" id="quantitative.s230.e1" text="sildenafil" type="active-ingredient" /><entity charOffset="168-177" id="quantitative.s230.e2" text="sildenafil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s230.e0" e2="quantitative.s230.e2" id="quantitative.s230.p0" /></sentence><sentence id="quantitative.s231" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy"><entity charOffset="0-12" id="quantitative.s231.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="15-27" id="quantitative.s231.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="143-155" id="quantitative.s231.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="84-91" id="quantitative.s231.e3" text="Felbatol" type="drug-product" /><entity charOffset="241-248" id="quantitative.s231.e4" text="Felbatol" type="drug-product" /><entity charOffset="284-291" id="quantitative.s231.e5" text="Felbatol" type="drug-product" /><pair ddi="true" e1="quantitative.s231.e2" e2="quantitative.s231.e5" id="quantitative.s231.p0" /></sentence><sentence id="quantitative.s232" text="Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy"><entity charOffset="61-68" id="quantitative.s232.e0" text="Felbatol" type="drug-product" /><entity charOffset="222-229" id="quantitative.s232.e1" text="Felbatol" type="drug-product" /><entity charOffset="265-272" id="quantitative.s232.e2" text="Felbatol" type="drug-product" /><entity charOffset="0-8" id="quantitative.s232.e3" text="Phenytoin" type="active-ingredient" /><entity charOffset="132-140" id="quantitative.s232.e4" text="Phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s232.e2" e2="quantitative.s232.e4" id="quantitative.s232.p0" /></sentence><sentence id="quantitative.s233" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week"><entity charOffset="35-43" id="quantitative.s233.e0" text="felbamate" type="active-ingredient" /><entity charOffset="359-367" id="quantitative.s233.e1" text="felbamate" type="active-ingredient" /><entity charOffset="0-12" id="quantitative.s233.e2" text="phenobarbital" type="active-ingredient" /><entity charOffset="50-62" id="quantitative.s233.e3" text="phenobarbital" type="active-ingredient" /><entity charOffset="86-98" id="quantitative.s233.e4" text="phenobarbital" type="active-ingredient" /><entity charOffset="173-185" id="quantitative.s233.e5" text="phenobarbital" type="active-ingredient" /><entity charOffset="219-231" id="quantitative.s233.e6" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="quantitative.s233.e1" e2="quantitative.s233.e6" id="quantitative.s233.p0" /></sentence><sentence id="quantitative.s234" text="In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL. The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively"><entity charOffset="216-224" id="quantitative.s234.e0" text="felbamate" type="active-ingredient" /><entity charOffset="261-269" id="quantitative.s234.e1" text="felbamate" type="active-ingredient" /><entity charOffset="41-49" id="quantitative.s234.e2" text="valproate" type="active-ingredient" /><entity charOffset="83-91" id="quantitative.s234.e3" text="valproate" type="active-ingredient" /><entity charOffset="318-326" id="quantitative.s234.e4" text="valproate" type="active-ingredient" /><entity charOffset="388-396" id="quantitative.s234.e5" text="valproate" type="active-ingredient" /><entity charOffset="548-556" id="quantitative.s234.e6" text="valproate" type="active-ingredient" /><entity charOffset="583-591" id="quantitative.s234.e7" text="valproate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s234.e1" e2="quantitative.s234.e7" id="quantitative.s234.p0" /></sentence><sentence id="quantitative.s235" text="In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered. Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0±0.3 to 1.6±0.4 micrograms/mL with the addition of felbamate."><entity charOffset="304-324" id="quantitative.s235.e0" text="Carbamazepine epoxide" type="metabolite" /><entity charOffset="234-242" id="quantitative.s235.e1" text="felbamate" type="active-ingredient" /><entity charOffset="434-442" id="quantitative.s235.e2" text="felbamate" type="active-ingredient" /><pair ddi="true" e1="quantitative.s235.e0" e2="quantitative.s235.e2" id="quantitative.s235.p0" /></sentence><sentence id="quantitative.s236" text="In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered"><entity charOffset="234-242" id="quantitative.s236.e0" text="felbamate" type="active-ingredient" /><entity charOffset="59-71" id="quantitative.s236.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="105-117" id="quantitative.s236.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="161-173" id="quantitative.s236.e3" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s236.e0" e2="quantitative.s236.e3" id="quantitative.s236.p0" /></sentence><sentence id="quantitative.s237" text="In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL. The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL"><entity charOffset="230-238" id="quantitative.s237.e0" text="felbamate" type="active-ingredient" /><entity charOffset="275-283" id="quantitative.s237.e1" text="felbamate" type="active-ingredient" /><entity charOffset="57-65" id="quantitative.s237.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="99-107" id="quantitative.s237.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="357-365" id="quantitative.s237.e4" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s237.e1" e2="quantitative.s237.e4" id="quantitative.s237.p0" /></sentence><sentence id="quantitative.s238" text="Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol"><entity charOffset="0-8" id="quantitative.s238.e0" text="Felbamate" type="active-ingredient" /><entity charOffset="54-62" id="quantitative.s238.e1" text="gestodene" type="active-ingredient" /><pair ddi="true" e1="quantitative.s238.e0" e2="quantitative.s238.e1" id="quantitative.s238.p0" /></sentence><sentence id="quantitative.s239" text="Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state"><entity charOffset="62-70" id="quantitative.s239.e0" text="valproate" type="active-ingredient" /><entity charOffset="92-99" id="quantitative.s239.e1" text="Felbatol" type="drug-product" /><pair ddi="false" e1="quantitative.s239.e0" e2="quantitative.s239.e1" id="quantitative.s239.p0" /></sentence><sentence id="quantitative.s240" text="Coadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate"><entity charOffset="45-54" id="quantitative.s240.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="20-38" id="quantitative.s240.e1" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="94-112" id="quantitative.s240.e2" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s240.e0" e2="quantitative.s240.e2" id="quantitative.s240.p0" /></sentence><sentence id="quantitative.s241" text="Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate"><entity charOffset="22-61" id="quantitative.s241.e0" text="magnesium and aluminum hydroxide antacid" type="drug-product" /><entity charOffset="85-103" id="quantitative.s241.e1" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="158-176" id="quantitative.s241.e2" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s241.e0" e2="quantitative.s241.e2" id="quantitative.s241.p0" /></sentence><sentence id="quantitative.s242" text="A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate"><entity charOffset="24-33" id="quantitative.s242.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="126-144" id="quantitative.s242.e1" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s242.e0" e2="quantitative.s242.e1" id="quantitative.s242.p0" /></sentence><sentence id="quantitative.s243" text="Single and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol"><entity charOffset="108-114" id="quantitative.s243.e0" text="ethanol" type="active-ingredient" /><entity charOffset="35-53" id="quantitative.s243.e1" text="amlodipine besylate" type="active-ingredient" /><pair ddi="false" e1="quantitative.s243.e0" e2="quantitative.s243.e1" id="quantitative.s243.p0" /></sentence><sentence id="quantitative.s244" text="Coadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers"><entity charOffset="20-38" id="quantitative.s244.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="45-51" id="quantitative.s244.e1" text="digoxin" type="active-ingredient" /><entity charOffset="74-80" id="quantitative.s244.e2" text="digoxin" type="active-ingredient" /><entity charOffset="92-98" id="quantitative.s244.e3" text="digoxin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s244.e0" e2="quantitative.s244.e3" id="quantitative.s244.p0" /></sentence><sentence id="quantitative.s245" text="Coadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin"><entity charOffset="44-62" id="quantitative.s245.e0" text="amlodipine besylate" type="active-ingredient" /><entity charOffset="78-89" id="quantitative.s245.e1" text="atorvastatin" type="active-ingredient" /><entity charOffset="175-186" id="quantitative.s245.e2" text="atorvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s245.e0" e2="quantitative.s245.e2" id="quantitative.s245.p0" /></sentence><sentence id="quantitative.s246" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%"><entity charOffset="49-56" id="quantitative.s246.e0" text="pimozide" type="active-ingredient" /><entity charOffset="158-165" id="quantitative.s246.e1" text="pimozide" type="active-ingredient" /><entity charOffset="66-75" id="quantitative.s246.e2" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s246.e1" e2="quantitative.s246.e2" id="quantitative.s246.p0" /></sentence><sentence id="quantitative.s247" text="In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion"><entity charOffset="101-112" id="quantitative.s247.e0" text="fexofenadine" type="active-ingredient" /><entity charOffset="78-89" id="quantitative.s247.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s247.e0" e2="quantitative.s247.e1" id="quantitative.s247.p0" /></sentence><sentence id="quantitative.s248" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole"><entity charOffset="0-11" id="quantitative.s248.e0" text="Fexofenadine" type="active-ingredient" /><entity charOffset="77-88" id="quantitative.s248.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="false" e1="quantitative.s248.e0" e2="quantitative.s248.e1" id="quantitative.s248.p0" /></sentence><sentence id="quantitative.s249" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole"><entity charOffset="61-72" id="quantitative.s249.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="0-11" id="quantitative.s249.e1" text="Fexofenadine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s249.e0" e2="quantitative.s249.e1" id="quantitative.s249.p0" /></sentence><sentence id="quantitative.s250" text="Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values"><entity charOffset="30-42" id="quantitative.s250.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="94-106" id="quantitative.s250.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="214-226" id="quantitative.s250.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="60-68" id="quantitative.s250.e3" text="trazodone" type="active-ingredient" /><entity charOffset="141-149" id="quantitative.s250.e4" text="trazodone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s250.e2" e2="quantitative.s250.e4" id="quantitative.s250.p0" /></sentence><sentence id="quantitative.s251" text="The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%"><entity charOffset="43-51" id="quantitative.s251.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="127-135" id="quantitative.s251.e1" text="trazodone" type="active-ingredient" /><entity charOffset="198-206" id="quantitative.s251.e2" text="trazodone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s251.e0" e2="quantitative.s251.e2" id="quantitative.s251.p0" /></sentence><sentence id="quantitative.s252" text="Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level"><entity charOffset="21-34" id="quantitative.s252.e0" text="chlorpromazine" type="active-ingredient" /><entity charOffset="41-51" id="quantitative.s252.e1" text="propranolol" type="active-ingredient" /><entity charOffset="83-93" id="quantitative.s252.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s252.e0" e2="quantitative.s252.e2" id="quantitative.s252.p0" /></sentence><sentence id="quantitative.s253" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%"><entity charOffset="33-43" id="quantitative.s253.e0" text="propranolol" type="active-ingredient" /><entity charOffset="211-222" id="quantitative.s253.e1" text="mesoridazine" type="metabolite" /><pair ddi="true" e1="quantitative.s253.e0" e2="quantitative.s253.e1" id="quantitative.s253.p0" /></sentence><sentence id="quantitative.s254" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%"><entity charOffset="112-123" id="quantitative.s254.e0" text="thioridazine" type="active-ingredient" /><entity charOffset="186-197" id="quantitative.s254.e1" text="thioridazine" type="active-ingredient" /><entity charOffset="33-43" id="quantitative.s254.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s254.e1" e2="quantitative.s254.e2" id="quantitative.s254.p0" /></sentence><sentence id="quantitative.s255" text="Propranolol did not have an effect on the pharmacokinetics of fluvastatin"><entity charOffset="0-10" id="quantitative.s255.e0" text="Propranolol" type="active-ingredient" /><entity charOffset="62-72" id="quantitative.s255.e1" text="fluvastatin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s255.e0" e2="quantitative.s255.e1" id="quantitative.s255.p0" /></sentence><sentence id="quantitative.s256" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics"><entity charOffset="38-47" id="quantitative.s256.e0" text="lovastatin" type="active-ingredient" /><entity charOffset="21-31" id="quantitative.s256.e1" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s256.e0" e2="quantitative.s256.e1" id="quantitative.s256.p0" /></sentence><sentence id="quantitative.s257" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics"><entity charOffset="52-62" id="quantitative.s257.e0" text="pravastatin" type="active-ingredient" /><entity charOffset="21-31" id="quantitative.s257.e1" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s257.e0" e2="quantitative.s257.e1" id="quantitative.s257.p0" /></sentence><sentence id="quantitative.s258" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations"><entity charOffset="39-48" id="quantitative.s258.e0" text="colestipol" type="active-ingredient" /><entity charOffset="55-65" id="quantitative.s258.e1" text="propranolol" type="active-ingredient" /><entity charOffset="101-111" id="quantitative.s258.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s258.e0" e2="quantitative.s258.e2" id="quantitative.s258.p0" /></sentence><sentence id="quantitative.s259" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations"><entity charOffset="21-34" id="quantitative.s259.e0" text="cholestyramine" type="active-ingredient" /><entity charOffset="55-65" id="quantitative.s259.e1" text="propranolol" type="active-ingredient" /><entity charOffset="101-111" id="quantitative.s259.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s259.e0" e2="quantitative.s259.e2" id="quantitative.s259.p0" /></sentence><sentence id="quantitative.s260" text="Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics"><entity charOffset="21-34" id="quantitative.s260.e0" text="metoclopramide" type="active-ingredient" /><entity charOffset="57-67" id="quantitative.s260.e1" text="propranolol" type="active-ingredient" /><entity charOffset="106-116" id="quantitative.s260.e2" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s260.e0" e2="quantitative.s260.e2" id="quantitative.s260.p0" /></sentence><sentence id="quantitative.s261" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively"><entity charOffset="38-47" id="quantitative.s261.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="21-31" id="quantitative.s261.e1" text="propranolol" type="active-ingredient" /><entity charOffset="93-103" id="quantitative.s261.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="quantitative.s261.e0" e2="quantitative.s261.e2" id="quantitative.s261.p0" /></sentence><sentence id="quantitative.s262" text="Diazepam does not alter the pharmacokinetics of propranolol."><entity charOffset="48-58" id="quantitative.s262.e0" text="propranolol" type="active-ingredient" /><entity charOffset="0-7" id="quantitative.s262.e1" text="Diazepam" type="active-ingredient" /><pair ddi="false" e1="quantitative.s262.e0" e2="quantitative.s262.e1" id="quantitative.s262.p0" /></sentence><sentence id="quantitative.s263" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil"><entity charOffset="0-10" id="quantitative.s263.e0" text="Propranolol" type="active-ingredient" /><entity charOffset="52-60" id="quantitative.s263.e1" text="verapamil" type="active-ingredient" /><entity charOffset="69-77" id="quantitative.s263.e2" text="verapamil" type="active-ingredient" /><pair ddi="false" e1="quantitative.s263.e0" e2="quantitative.s263.e2" id="quantitative.s263.p0" /></sentence><sentence id="quantitative.s264" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil"><entity charOffset="0-10" id="quantitative.s264.e0" text="Propranolol" type="active-ingredient" /><entity charOffset="66-77" id="quantitative.s264.e1" text="norverapamil" type="metabolite" /><pair ddi="false" e1="quantitative.s264.e0" e2="quantitative.s264.e1" id="quantitative.s264.p0" /></sentence><sentence id="quantitative.s265" text="Verapamil does not affect the pharmacokinetics of propranolol"><entity charOffset="0-8" id="quantitative.s265.e0" text="Verapamil" type="active-ingredient" /><entity charOffset="50-60" id="quantitative.s265.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="quantitative.s265.e0" e2="quantitative.s265.e1" id="quantitative.s265.p0" /></sentence><sentence id="quantitative.s266" text="The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade."><entity charOffset="18-28" id="quantitative.s266.e0" text="propranolol" type="active-ingredient" /><entity charOffset="65-73" id="quantitative.s266.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s266.e0" e2="quantitative.s266.e1" id="quantitative.s266.p0" /></sentence><sentence id="quantitative.s267" text="The AUC of propafenone is increased by more than 200% by co-administration of propranolol."><entity charOffset="78-88" id="quantitative.s267.e0" text="propranolol" type="active-ingredient" /><entity charOffset="11-21" id="quantitative.s267.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s267.e0" e2="quantitative.s267.e1" id="quantitative.s267.p0" /></sentence><sentence id="quantitative.s268" text="Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone"><entity charOffset="198-210" id="quantitative.s268.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="60-68" id="quantitative.s268.e1" text="metformin" type="active-ingredient" /><entity charOffset="185-193" id="quantitative.s268.e2" text="metformin" type="active-ingredient" /><pair ddi="false" e1="quantitative.s268.e0" e2="quantitative.s268.e2" id="quantitative.s268.p0" /></sentence><sentence id="quantitative.s269" text="Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA"><entity charOffset="21-31" id="quantitative.s269.e0" text="glimepiride" type="active-ingredient" /><entity charOffset="139-145" id="quantitative.s269.e1" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s269.e0" e2="quantitative.s269.e1" id="quantitative.s269.p0" /></sentence><sentence id="quantitative.s270" text="Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers"><entity charOffset="101-108" id="quantitative.s270.e0" text="warfarin" type="active-ingredient" /><entity charOffset="19-25" id="quantitative.s270.e1" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s270.e0" e2="quantitative.s270.e1" id="quantitative.s270.p0" /></sentence><sentence id="quantitative.s271" text="Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone"><entity charOffset="60-68" id="quantitative.s271.e0" text="metformin" type="active-ingredient" /><entity charOffset="185-193" id="quantitative.s271.e1" text="metformin" type="active-ingredient" /><entity charOffset="29-35" id="quantitative.s271.e2" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s271.e1" e2="quantitative.s271.e2" id="quantitative.s271.p0" /></sentence><sentence id="quantitative.s272" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), "><entity charOffset="0-6" id="quantitative.s272.e0" text="AVANDIA" type="drug-product" /><entity charOffset="102-111" id="quantitative.s272.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s272.e0" e2="quantitative.s272.e1" id="quantitative.s272.p0" /></sentence><sentence id="quantitative.s273" text="Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA."><entity charOffset="20-27" id="quantitative.s273.e0" text="acarbose" type="active-ingredient" /><entity charOffset="172-178" id="quantitative.s273.e1" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s273.e0" e2="quantitative.s273.e1" id="quantitative.s273.p0" /></sentence><sentence id="quantitative.s274" text="No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects"><entity charOffset="101-107" id="quantitative.s274.e0" text="AVANDIA" type="drug-product" /><entity charOffset="40-50" id="quantitative.s274.e1" text="glimepiride" type="active-ingredient" /><pair ddi="false" e1="quantitative.s274.e0" e2="quantitative.s274.e1" id="quantitative.s274.p0" /></sentence><sentence id="quantitative.s275" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), "><entity charOffset="0-6" id="quantitative.s275.e0" text="AVANDIA" type="drug-product" /><entity charOffset="160-172" id="quantitative.s275.e1" text="norethindrone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s275.e0" e2="quantitative.s275.e1" id="quantitative.s275.p0" /></sentence><sentence id="quantitative.s276" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), "><entity charOffset="138-154" id="quantitative.s276.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="0-6" id="quantitative.s276.e1" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s276.e0" e2="quantitative.s276.e1" id="quantitative.s276.p0" /></sentence><sentence id="quantitative.s277" text="Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers"><entity charOffset="111-117" id="quantitative.s277.e0" text="digoxin" type="active-ingredient" /><entity charOffset="22-28" id="quantitative.s277.e1" text="AVANDIA" type="drug-product" /><pair ddi="false" e1="quantitative.s277.e0" e2="quantitative.s277.e1" id="quantitative.s277.p0" /></sentence><sentence id="quantitative.s278" text="Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers"><entity charOffset="18-27" id="quantitative.s278.e0" text="ranitidine" type="active-ingredient" /><entity charOffset="142-154" id="quantitative.s278.e1" text="rosiglitazone" type="active-ingredient" /><pair ddi="false" e1="quantitative.s278.e0" e2="quantitative.s278.e1" id="quantitative.s278.p0" /></sentence><sentence id="quantitative.s279" text="Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone."><entity charOffset="92-104" id="quantitative.s279.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="145-157" id="quantitative.s279.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="206-218" id="quantitative.s279.e2" text="rosiglitazone" type="active-ingredient" /><entity charOffset="30-40" id="quantitative.s279.e3" text="gemfibrozil" type="active-ingredient" /><pair ddi="true" e1="quantitative.s279.e2" e2="quantitative.s279.e3" id="quantitative.s279.p0" /></sentence><sentence id="quantitative.s280" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). "><entity charOffset="394-410" id="quantitative.s280.e0" text="desmethyldiazepam" type="metabolite" /><entity charOffset="123-132" id="quantitative.s280.e1" text="sertraline" type="active-ingredient" /><entity charOffset="257-266" id="quantitative.s280.e2" text="sertraline" type="active-ingredient" /><entity charOffset="419-428" id="quantitative.s280.e3" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="quantitative.s280.e0" e2="quantitative.s280.e3" id="quantitative.s280.p0" /></sentence><sentence id="quantitative.s281" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). "><entity charOffset="123-132" id="quantitative.s281.e0" text="sertraline" type="active-ingredient" /><entity charOffset="257-266" id="quantitative.s281.e1" text="sertraline" type="active-ingredient" /><entity charOffset="67-74" id="quantitative.s281.e2" text="diazepam" type="active-ingredient" /><entity charOffset="230-237" id="quantitative.s281.e3" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s281.e1" e2="quantitative.s281.e3" id="quantitative.s281.p0" /></sentence><sentence id="quantitative.s282" text="Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine"><entity charOffset="20-32" id="quantitative.s282.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="123-132" id="quantitative.s282.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s282.e0" e2="quantitative.s282.e1" id="quantitative.s282.p0" /></sentence><sentence id="quantitative.s283" text="Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%"><entity charOffset="20-29" id="quantitative.s283.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="55-64" id="quantitative.s283.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="149-158" id="quantitative.s283.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="88-96" id="quantitative.s283.e3" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s283.e2" e2="quantitative.s283.e3" id="quantitative.s283.p0" /></sentence><sentence id="quantitative.s284" text="Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy"><entity charOffset="30-54" id="quantitative.s284.e0" text="quinupristin/dalfopristin" type="active-ingredient" /><entity charOffset="60-69" id="quantitative.s284.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="141-150" id="quantitative.s284.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="207-216" id="quantitative.s284.e3" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s284.e0" e2="quantitative.s284.e3" id="quantitative.s284.p0" /></sentence><sentence id="quantitative.s285" text="In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine"><entity charOffset="90-99" id="quantitative.s285.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="179-188" id="quantitative.s285.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="131-140" id="quantitative.s285.e2" text="cimetidine" type="active-ingredient" /><entity charOffset="209-218" id="quantitative.s285.e3" text="cimetidine" type="active-ingredient" /><entity charOffset="277-286" id="quantitative.s285.e4" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s285.e1" e2="quantitative.s285.e4" id="quantitative.s285.p0" /></sentence><sentence id="quantitative.s286" text="The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02."><entity charOffset="49-58" id="quantitative.s286.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="19-28" id="quantitative.s286.e1" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s286.e0" e2="quantitative.s286.e1" id="quantitative.s286.p0" /></sentence><sentence id="quantitative.s287" text="In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively"><entity charOffset="19-27" id="quantitative.s287.e0" text="doxazosin" type="active-ingredient" /><entity charOffset="46-55" id="quantitative.s287.e1" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s287.e0" e2="quantitative.s287.e1" id="quantitative.s287.p0" /></sentence><sentence id="quantitative.s288" text="Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively"><entity charOffset="73-81" id="quantitative.s288.e0" text="doxazosin" type="active-ingredient" /><entity charOffset="20-29" id="quantitative.s288.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="130-139" id="quantitative.s288.e2" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s288.e0" e2="quantitative.s288.e2" id="quantitative.s288.p0" /></sentence><sentence id="quantitative.s289" text="However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics"><entity charOffset="70-79" id="quantitative.s289.e0" text="irbesartan" type="active-ingredient" /><entity charOffset="42-51" id="quantitative.s289.e1" text="nifedipine" type="active-ingredient" /><pair ddi="false" e1="quantitative.s289.e0" e2="quantitative.s289.e1" id="quantitative.s289.p0" /></sentence><sentence id="quantitative.s290" text="Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively"><entity charOffset="62-70" id="quantitative.s290.e0" text="diltiazem" type="active-ingredient" /><entity charOffset="98-107" id="quantitative.s290.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="138-147" id="quantitative.s290.e2" text="nifedipine" type="active-ingredient" /><entity charOffset="223-232" id="quantitative.s290.e3" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s290.e0" e2="quantitative.s290.e3" id="quantitative.s290.p0" /></sentence><sentence id="quantitative.s291" text="Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively"><entity charOffset="38-54" id="quantitative.s291.e0" text="quinidine sulfate" type="active-ingredient" /><entity charOffset="76-85" id="quantitative.s291.e1" text="nifedipine" type="active-ingredient" /><entity charOffset="128-137" id="quantitative.s291.e2" text="nifedipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s291.e0" e2="quantitative.s291.e2" id="quantitative.s291.p0" /></sentence><sentence id="quantitative.s292" text="In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol"><entity charOffset="115-124" id="quantitative.s292.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="216-225" id="quantitative.s292.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="66-76" id="quantitative.s292.e2" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="quantitative.s292.e1" e2="quantitative.s292.e2" id="quantitative.s292.p0" /></sentence><sentence id="quantitative.s293" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life"><entity charOffset="124-133" id="quantitative.s293.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="173-182" id="quantitative.s293.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="200-209" id="quantitative.s293.e2" text="metoprolol" type="active-ingredient" /><entity charOffset="85-93" id="quantitative.s293.e3" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s293.e2" e2="quantitative.s293.e3" id="quantitative.s293.p0" /></sentence><sentence id="quantitative.s294" text="The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day"><entity charOffset="29-38" id="quantitative.s294.e0" text="conivaptan" type="active-ingredient" /><entity charOffset="104-112" id="quantitative.s294.e1" text="captopril" type="active-ingredient" /><pair ddi="false" e1="quantitative.s294.e0" e2="quantitative.s294.e1" id="quantitative.s294.p0" /></sentence><sentence id="quantitative.s295" text="VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively"><entity charOffset="0-7" id="quantitative.s295.e0" text="VAPRISOL" type="drug-product" /><entity charOffset="123-131" id="quantitative.s295.e1" text="midazolam" type="active-ingredient" /><pair ddi="true" e1="quantitative.s295.e0" e2="quantitative.s295.e1" id="quantitative.s295.p0" /></sentence><sentence id="quantitative.s296" text="Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively"><entity charOffset="37-43" id="quantitative.s296.e0" text="digoxin" type="active-ingredient" /><entity charOffset="197-203" id="quantitative.s296.e1" text="digoxin" type="active-ingredient" /><entity charOffset="84-107" id="quantitative.s296.e2" text="conivaptan hydrochloride" type="active-ingredient" /><pair ddi="true" e1="quantitative.s296.e1" e2="quantitative.s296.e2" id="quantitative.s296.p0" /></sentence><sentence id="quantitative.s297" text="he pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day"><entity charOffset="28-37" id="quantitative.s297.e0" text="conivaptan" type="active-ingredient" /><entity charOffset="122-131" id="quantitative.s297.e1" text="furosemide" type="active-ingredient" /><pair ddi="false" e1="quantitative.s297.e0" e2="quantitative.s297.e1" id="quantitative.s297.p0" /></sentence><sentence id="quantitative.s298" text="Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively"><entity charOffset="25-34" id="quantitative.s298.e0" text="conivaptan" type="active-ingredient" /><entity charOffset="137-146" id="quantitative.s298.e1" text="conivaptan" type="active-ingredient" /><entity charOffset="61-72" id="quantitative.s298.e2" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="quantitative.s298.e1" e2="quantitative.s298.e2" id="quantitative.s298.p0" /></sentence><sentence id="quantitative.s299" text="Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine"><entity charOffset="5-28" id="quantitative.s299.e0" text="conivaptan hydrochloride" type="active-ingredient" /><entity charOffset="106-115" id="quantitative.s299.e1" text="amlodipine" type="active-ingredient" /><pair ddi="true" e1="quantitative.s299.e0" e2="quantitative.s299.e1" id="quantitative.s299.p0" /></sentence><sentence id="quantitative.s300" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin"><entity charOffset="0-7" id="quantitative.s300.e0" text="VAPRISOL" type="drug-product" /><entity charOffset="63-73" id="quantitative.s300.e1" text="simvastatin" type="active-ingredient" /><pair ddi="true" e1="quantitative.s300.e0" e2="quantitative.s300.e1" id="quantitative.s300.p0" /></sentence><sentence id="quantitative.s301" text="VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively"><entity charOffset="73-80" id="quantitative.s301.e0" text="warfarin" type="active-ingredient" /><entity charOffset="178-185" id="quantitative.s301.e1" text="warfarin" type="active-ingredient" /><entity charOffset="197-204" id="quantitative.s301.e2" text="warfarin" type="active-ingredient" /><entity charOffset="0-7" id="quantitative.s301.e3" text="VAPRISOL" type="drug-product" /><pair ddi="true" e1="quantitative.s301.e2" e2="quantitative.s301.e3" id="quantitative.s301.p0" /></sentence></document>